



Developing and validating a scoring tool for identifying people who inject drugs at increased risk of hepatitis C virus infection

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000387
Article Type:	Research
Date Submitted by the Author:	07-Sep-2011
Complete List of Authors:	Wand, Handan; University of New South wales Iversen, Jenny; The Kirby Institute Wilson, David; The Kirby Institute Topp, Libby; The Kirby Institute Maher, Lisa; The Kirby Institute
Primary Subject Heading:	Epidemiology
Keywords:	INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES, Infection control < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 **Developing and validating a scoring tool for identifying people who inject drugs**
7 **at increased risk of hepatitis C virus infection**
8
9

10
11
12
13
14 Handan Wand, Jenny Iversen, David Wilson, Libby Topp and Lisa Maher
15

16
17
18 The Kirby Institute, Sydney, Australia, University of New South Wales
19

20
21 September 3, 2011
22

23
24 Final
25
26

27 **Corresponding author:**
28

29
30 Handan Wand, PhD
31

32 The Kirby Institute, University of New South Wales, Sydney, Australia
33

34 Telephone: +61-2-9385 0900
35

36 Facsimile: +61-2-9385 0920
37

38 email: hwand@nchecr.unsw.edu.au
39
40

41 Word counts:
42

43 Abstract: 200
44

45 Manuscript: 2,615
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Objective:** To develop and a validate a scoring tool based on demographic and injecting risk behaviors
4 to identify those who require additional, non-routine serological screening for HCV by assessing their
5 personal risk.
6
7
8

9
10
11 **Methods:** The analysis included 16,127 participants who attended Needle and Syringe Programs (NSP) in
12 Australia (1998-2008). Univariate and multivariate logistic regression models were used to develop a
13 prediction model by age groups.
14
15
16

17
18
19 **Results:** Type of drug last injected, frequency and duration of injecting, sharing needles and syringes or
20 other injecting equipments and imprisonment history were associated with HCV infection in all age
21 groups. Strong relationship between an individual's 'HCV score' and their risk of testing HCV antibody
22 positive was observed. An estimated 78% (95% CI: 75%, 81%), 82% (95% CI: 80%, 84%) and 80% (95% CI:
23 77%, 82%) of HCV infections across the age groups would be avoided if participants who were in the
24 upper four quintiles of HCV scores had reduced risk to be in the lowest quintile of HCV scores.
25
26
27
28
29
30
31

32
33 **Conclusion:** Knowledge of HCV status has important implications for public health and care and
34 treatment. Risk assessment strategies may assist to alert PWID who are at increased risk of HCV
35 infection to present for testing.
36
37
38
39
40
41
42
43
44

45 **Key words:** Hepatitis C infection, injecting drug users, risk assessment
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Worldwide, infection with hepatitis C virus (HCV) is common among people who inject drugs (PWID) [1]. Estimates suggest that more than 70% of new cases of HCV infection are associated with injecting drug use [2,3]. Epidemiologic studies have identified independent risk factors for HCV infection, including sharing of contaminated needles and syringes [4-7] and other injecting equipment [8, 9], female gender [10,11], duration of injecting [12] and intravenous cocaine use [13, 14]. Although the risk factors for incident infection are well established, the literature suggests that a number of barriers may prevent PWID presenting for screening and many PWID face the possibility of HCV infection with a sense of inevitability, fostered by structural barriers to risk avoidance [15, 16]. PWID are a priority population in Australia as HCV prevalence remains high in this group. The burden of advanced liver disease (liver failure and hepatocellular carcinoma) continues to grow among HCV-infected people [17]. It is estimated that 5,300 Australians are living with HCV-related cirrhosis and this figure is expected to double by 2020 without increased therapeutic intervention [18]. Despite the mounting burden of disease and recent advances in antiviral treatments, HCV treatment uptake among PWID remains very low (1-2% of chronic hepatitis C cases) [17]. A major public health challenge is to more effectively identify individuals with HCV before the development of significant clinical consequences.

Our study aimed to develop a scoring tool that can be used by PWID and primary care providers to identify individuals at increased risk of HCV infection. With increasing recognition of the clinical benefits of early diagnosis and treatment uptake [19-21], a simple self-administered tool may provide a way for PWID to identify personal risk and to modify risk behavior and/or seek health care/further assessment.

1
2
3 A large database of serial cross sectional samples of PWID attending Needle and Syringe Programs (NSP)
4
5 in Australia (1998 -2008) was used to develop a statistical model underpinning the tool. Retrospective
6
7 validation was carried out on the HCV risk assessment algorithm.
8
9

10
11 The following characteristics were considered essential in the development of the new prediction
12
13 algorithm: (1) the use of routinely available and minimally intrusive variables and (2) estimation of the
14
15 cumulative effect of concurrent risk factors on the likelihood of HCV prevalence. We are unaware of any
16
17 studies to date that have quantified the cumulative effect of concurrent risk factors on the acquisition of
18
19 HCV infection among PWID.
20
21

22 23 24 25 **STUDY POPULATION**

26
27
28
29
30 The Australian Needle and Syringe Program Survey (ANSPS) is a serial cross-sectional study conducted
31
32 annually over a one to two week period since 1995. More than 50 NSP sites participate annually, with
33
34 sites selected on the basis of geographic coverage, willingness to participate and an ability to recruit a
35
36 minimum of 20 survey respondents. The survey methods have been described in detail elsewhere [22-
37
38 25]. In brief, all PWID who attended participating ANSPS sites during the designated survey period were
39
40 invited to participate. Participation was anonymous and voluntary and there was no financial
41
42 reimbursement. Participants were asked to complete a brief, self-administered questionnaire on
43
44 demographic characteristics and injecting and sexual risk behaviors
45
46 (www.web.med.unsw.edu.au/nchecr), and to provide a capillary blood sample for antibody HIV and HCV
47
48 testing. The current study used data for the period 1998-2008, involving more than 16,000 individuals.
49
50

51
52
53 Capillary blood was obtained by finger prick using single-use, disposable lancets and cotton-fiber
54
55 blotting paper. Specimens were kept at room temperature at the survey sites, then couriered to a
56
57
58
59
60

1
2
3 central collection point before they were forwarded to the laboratory. A modified, third generation
4
5 enzyme immunoassay (Abbott hepatitis C 3.0, Chicago, IL, USA) was used to test for HCV antibody. A
6
7 modified cutoff value for optical density was calculated to capture greater than 95% of the seronegative
8
9 population. Specimens were considered positive for HCV antibody if the optical density to cutoff ratio
10
11 was greater than or equal to one on initial and subsequent testing.
12
13

14
15
16
17
18 Ethical approval was obtained from the Human Research Ethics Committee (HREC) at the University of
19
20 New South Wales, as well as from relevant jurisdictional and site specific HRECs.
21
22
23

24 25 26 27 **STATISTICAL ANALYSES**

28
29
30 A split-sample method was used to develop and subsequently validate a risk equation and scoring
31
32 system. Participants were randomly allocated to either the development (n=10,662; 67%) or internal
33
34 validation (n=5,331; 33%) sample datasets.
35
36
37

38
39
40 We selected a range of demographic and injecting behavior variables as potential determinants of HCV
41
42 infection. These included gender, Indigenous status, imprisonment history, country of birth, language
43
44 spoken at home, drug last injected, frequency and duration of injecting, sharing of needles and syringes
45
46 and other injecting equipment (e.g. water, filter, spoon, tourniquet), public injecting, and drug
47
48 treatment history. All analyses were stratified by age groups (<25, 25-29, 30-39 and 40+).
49
50

51
52 We used descriptive statistics to characterize the groups according to antibody HCV serostatus: mean
53
54 and standard deviation (SD) for continuous variables and percentages for categorical variables. Logistic
55
56 regression was used to create a predictive model based on the development data set. We used all non-
57
58
59
60

1
2
3 missing observations available in the relevant analyses as only a small proportion of observations had
4 any missing data (except for the variable “imprisonment history”). All analyses were conducted using
5 SAS statistical software version 9.2 (SAS Institute Inc. Cary, North Carolina) and STATA 10.0 (College
6 Station, Texas).
7
8
9
10

11 **Derivation of a screening score:**

12
13 Using the development data set (n=10,662), we included a comprehensive list of predictors known to be
14 associated with HCV antibody seropositivity in an initial model. Specifically, we included the main effects
15 of all variables listed in Table 1 and their interaction effects. We first analyzed the univariate
16 associations between the independent variables and HCV seropositivity. Backward elimination was used
17 to reach the final multivariate model, in which factors with the largest *P* value were sequentially deleted
18 until only significant predictors remained. We then created a weighted scoring system by rounding all
19 regression coefficients up to the nearest integer (that is, the smallest integer greater than the estimate).
20 This method was based on the β -coefficients (or log of the odds ratios) rather than odds ratios, which
21 can be excessively influenced by only a few factors [26]. Once the final model was defined, we created
22 integer weights for each variable. We calculated these weights by multiplying the model coefficients by
23 10. Using the rounded weights in the risk function, we estimated the participant-specific probabilities
24 of HCV seropositivity and characterized the degrees of risk based on cut-off points of the probability
25 distribution.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 **Cross-sectional and prospective validation:**

47
48 We examined the predictive validity of the scoring system using the internal validation datasets
49 (n=5,331). We also assessed the predictive validity of this scoring system on the subsequent of HCV
50 antibody seroconversion using prospective data collected from individuals who visited ANSPS sites
51 multiple times and tested HCV seronegative at their first visit.
52
53
54
55
56
57
58
59
60

1
2
3 We used the cross-sectional dataset to check the sensitivity and robustness of the new screening score.
4
5 We computed standard validation measures: the proportion of antibody HCV seropositive specimens,
6
7 sensitivity, specificity, positive likelihood and negative likelihood ratio and the area under the receiver
8
9 operating characteristic curve (AUC) as discrimination statistics. We also assessed the diagnostic
10
11 characteristics of different cut-points based on the total score in the development as well as validation
12
13 datasets. The purpose of this analysis was to assess whether the combination of risk factors under
14
15 consideration could predict those at increased risk with acceptable accuracy.
16
17
18
19
20
21
22

Population attributable risk:

23
24
25 After we calculated and validated the HCV screening score, we estimated population attributable risks,
26
27 which estimates the percentage of HCV infections that would not have occurred if all the participants
28
29 had been in the “lowest risk” (first quintile) category of the HCV screening score. We calculated
30
31 population attributable risks by using a previously described method [29] that was applied to this study
32
33 design and appropriate for use with multivariate adjusted relative risks.
34
35
36
37
38
39

RESULTS

40
41
42 Our study population comprised 10,662 individuals in the development dataset. Table 1 summarizes
43
44 participant characteristics by HCV antibody serostatus. The overall prevalence of HCV was 51%. HCV
45
46 seropositive participants tended to be older and more likely to report a longer duration of injecting,
47
48 heroin as the drug last injected, a history of imprisonment, daily or more frequent injecting, public
49
50 injecting and sharing needles and syringes and other injecting equipment.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2 presents the final multivariate logistic regression model derived from the development data set by age groups. History of imprisonment, duration of injecting (5-9, 10+ years), drug last injected (heroin, cocaine, methadone, morphine, buprenorphine and others), needle and syringe sharing and sharing of ancillary equipment were all significantly associated with increased risk of antibody HCV seropositivity across all age groups. Injecting frequency (daily or more) was determined to be a significant risk factor for those aged less than 30 years. Female gender was associated with an increased risk of HCV seroprevalence for those younger than 40 years of age. Indigenous status was a significant predictor for HCV infection among people aged 30-39 years. Drug last injected and duration of injecting each required multiple categories to capture the risk gradient, whereas other risk factors were binary. The risk factors collectively yielded an AUC of 0.73 (95% CI: 0.70, 0.76), 0.72 (95% CI: 0.70, 0.75), 0.73 (95% CI: 0.70, 0.76) and 0.66 (95% CI: 0.64, 0.71) for the age groups <25, 25-29, 30-39 and 40 plus (data not shown). There were no significant interactions between injecting risk behaviors and gender across age groups (data not shown).

Table 3 shows the odds ratios (ORs) from the logistic regression models and population attributable risks of HCV infection for the quintiles of the risk scores by age groups for the development and validation datasets. There was a linear trend towards increasing HCV infection with increasing score regardless of the age groups in both datasets (trend, p -value<0.001). Using the development dataset, we estimated population attributable risks (95% CI) for the upper four quintiles of the scores. Results showed that 78% (75%, 81%), 82% (80%, 84%) and 80% (77%, 82%) of HCV infections across the age groups would be avoided if participants in the upper four quintiles of the HCV scores instead fell into the lowest quintile. Results from the validation dataset were consistent with those from the development dataset (Table 3).

We also assessed the diagnostic characteristics of cut-points (according to first, second, third and the fourth quintiles in overall population) for total score in the development as well as the validation

1
2
3 datasets (Table 4). An increased risk of HCV was clearly associated with increasing scores. For example,
4
5 a cut-point score of 10 or higher distinguished a 'increased risk' group with a sensitivity of 96% or
6
7 higher; similarly a cut-point 20 or higher yielded at least 92% sensitivity in all age groups in the
8
9 development dataset; in cross sectional validation, sensitivity was estimated to be at least 94% across
10
11 the age groups for the cut-point 10/15 or more and at least 76% for 20 or more.
12
13

14
15 Figure 1 illustrates the risk of PWID being HCV seropositive as a continuous function of the total score.
16
17 Across all age groups, increasing scores were clearly associated with increased risk of HCV antibody
18
19 positivity.
20
21

22 23 24 25 **DISCUSSION**

26
27 In this study, we developed a scoring tool based on data from ~16,000 PWID who attended ANSPS sites
28
29 between 1998 and 2008. The tool was validated to accurately identify those at increased risk of HCV
30
31 infection. Current Australian guidelines recommend HCV antibody screening in all individuals with risk
32
33 factors for infection regardless of patient characteristics and settings [30]. Increasing the rate of HCV
34
35 diagnosis and, in particular, diagnosis of acute infection and providing access to effective antiviral
36
37 treatment has the potential to improve individual quality of life and reduce the burden of HCV infection.
38
39 Being unaware of one's HCV serostatus has been identified as the major barrier to increasing HCV
40
41 treatment uptake [31]. While a relatively high proportion (64%) of participants in the ANSPS reported
42
43 recent HCV testing, HCV antibody negative respondents were less likely to do so than antibody positive
44
45 respondents (60% versus 67%). One in five (20%) HCV antibody negative participants had not been
46
47 tested for HCV in the last twelve months, and a further 20% had never been tested
48
49 (www.web.med.unsw.edu.au/nchecr/Publications). This suggests that both uptake and frequency of
50
51 testing could be improved. The intention of this study was not to identify a unique and specific cut-point
52
53 of risk above which to target screening, but rather, to assess whether risk factors under consideration
54
55
56
57
58
59
60

1
2
3 could predict those at increased risk accurately in order to consider the tool's use in facilitating
4 increased screening. With a high background HCV prevalence of ~70% among Australian PWID, all PWID
5
6 increased screening. With a high background HCV prevalence of ~70% among Australian PWID, all PWID
7
8 should be screened for HCV. However, identification of only one of our listed risk factors substantially
9
10 increased the likelihood of infection. Although Australia has screening guidelines for hepatitis C, current
11
12 guidelines do not specifically target PWID [30]. By focusing on specific high-risk behaviors, tools such as
13
14 the one developed in this study may allow for more targeted identification of individuals at increased
15
16 risk of infection. If used as a self-administered questionnaire, it is likely that respondents will answer
17
18 more accurately [32]. Since the vast majority of new HCV diagnoses in Australia are among people with
19
20 a history of injecting drug use, this tool provides a valuable resource which could inform the
21
22 establishment of more focused national screening guidelines.
23
24
25
26

27 Further, although current clinical practice guidelines recommend HCV screening of individuals with a
28
29 history of injecting drugs, this recommendation focuses on a single risk factor (i.e. injecting drug use)
30
31 whereas considering the cumulative effect of multiple risk factors among PWID can more precisely
32
33 identify people in need of additional, non-routine screening. This is particularly pertinent in resource-
34
35 constrained environments (including time-restricted clinical settings). Our methodology made use of a
36
37 range of coexisting risk factors that were identified by a rigorous statistical approach in order to
38
39 accurately identify the most relevant factors for HCV infection.
40
41
42
43

44 Risk calculation approaches have been extensively used in decision making about public health and
45
46 clinical care and have even been proposed as an alternative to diagnosis for some diseases [33]. Our risk
47
48 calculation was based on a statistical method that yielded a systematic scoring system for carefully
49
50 selected predictors, guided not only by numerical and scientific evidence but also feasibility
51
52 perspectives. We chose categorized variables which highlighted the important risk factors to motivate
53
54
55
56
57
58
59
60

1
2
3 high-risk persons to be screened or to modify behaviors. This combination of factors may explain the
4
5 enhanced properties of our scoring tool.
6
7

8
9 Our study has several strengths, including being the first to validate a predictive model through
10
11 prospective testing in internal cross sectional and prospective data sets. Our prediction equation is
12
13 based on 11 years of data and more than 16,000 participants. Ideal risk assessment methods or
14
15 prediction models should be derived from large representative samples. The current study has several
16
17 limitations. First, the study population is limited to those who participated in the ANSPS, which may
18
19 result in selection bias. However, the ANSPS has been shown to be broadly representative of PWID
20
21 attending NSPs [16]. Second, we were not able to differentiate between acute, recent and chronic
22
23 infections.
24
25
26
27

28 Risk factor screening and identification allows for patients to be educated regarding the risks of injection
29
30 drug use and needle sharing. Appropriate testing and diagnosis of HCV allows for the patient to be
31
32 evaluated for treatment and receive counseling regarding HCV prevention. In addition to physician
33
34 education, patient education campaigns must also be developed to increase patient compliance with
35
36 testing recommendations made by their physicians.
37
38
39
40

41
42 In conclusion, we believe the screening tool described here will provide a simple and cost-effective
43
44 method of identifying and alerting PWID who are in need of additional, non-routine HCV screening with
45
46 notable predictive validity. A self-assessment method that helps individual PWID understand their
47
48 relatively increased risk of infection may encourage increased uptake and regularity of screening among
49
50 this population.
51
52
53
54
55
56
57
58
59
60

Article Summary**Article focus:**

- Although the risk factors for incident infection are well established, the literature suggests that a number of barriers may prevent PWID presenting for screening.
- Study developed a scoring tool based on demographic and injecting risk behaviors to identify those who require additional, non-routine serological screening for HCV by assessing their personal risk.

Key Messages:

- Current clinical practice guidelines recommend HCV screening of individuals with a history of injecting drugs.
- However, this recommendation focuses on a single risk factor (i.e. injecting drug use) whereas considering the cumulative effect of multiple risk factors among PWID can more precisely identify people in need of additional, non-routine screening.

Strengths and limitations:

- Our prediction equation is based on 11 years of data and more than 16,000 participants. Ideal risk assessment methods or prediction models should be derived from large representative samples.
- The study population is limited to those who participated in the ANSPS, which may result in selection bias.
- We were not able to differentiate between acute, recent and chronic infections.

1
2
3
4
5
6 **Competing interest:** None.
7

8 **Ethics approval:** Ethical approvals for the survey were obtained from Institutional Ethics Committees
9 associated with the investigators and participating NSP sites.
10
11

12
13 **Contributors:** HW implemented the study, analysed the data and wrote the first draft. LM, JI, LT and DW
14 helped interpreting the data and finalizing the manuscript. All authors saw and approved the final,
15 submitted version of the manuscript.
16
17

18
19 The Corresponding Author has the right to grant on behalf of all authors and does grant on
20 behalf of all authors, an exclusive licence (or non exclusive for government employees) on a
21 worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if
22 accepted) to be published in BMJ editions and any other BMJ PGL products and sublicences to
23 exploit all subsidiary rights, as set out in our licence (
24 <http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>)."
25 should be
26 made in the manuscript.
27
28
29
30
31
32

33
34 **Funding Source:** Australian Government Department of Health and Ageing.
35
36

37
38 **Provenance and peer review:** Not commissioned; externally peer reviewed.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES

- [1] McGinn T, O'Connor-Moore N, Alfandre D, Wisnivesky J. Validation of a Hepatitis C Screening Tool in Primary Care. *Arch Intern Med* **2008**; 168(18):2009-13.
- [2] Thorpe LE, Ouellet LJ, Hershov R et al. Risk of Hepatitis C Virus infection among Young Adult Injecting Drug Users Who Share Injecting Equipment. *American Journal of Epidemiology* **2002**; 155:7:645-653.
- [3] Alter MJ, Kruszon-Moran D et al. The prevalence of hepatitis C virus infection in the United States, 1998 through 1994. *New England Medical Journal* **1999**; 341:556-62.
- [4] Villano S. A., Vlahov D., Nelson K. E., Lyles C. M., Cohn S. & Thomas D. L. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. *J Clin Microbiol* 1997; **35**: 3274-7;
- [5] Garfein RS, Doherty MC, Monterroso ER, et al. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. *J Acq Immune Defic Synd Hum Retrovirol* **1998**; 18:11-19.
- [6] Hahn JA, Page-Shafer K, Lum PJ et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. *J Infect Dis* **2002**; 186:1558-64.
- [7] Hagan H, Thiede H, Des Jarlais DC. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. *Epidemiology* **2004**; 15: 543-9.
- [8] Hagan H, Thiede H, Weiss NS et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. *Am J Public Health* **2001**; 91: 42-6.
- [9] Falster K, Kaldor J and Maher L. Hepatitis C Virus acquisition among Injecting Drug Users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004. *Journal of Urban Health* **2008** [doi:10.1007/s11524-008-9330-7].

- 1
2
3 [10] Hahn JA, Page-Shafer K, Lum PJ et al. Hepatitis C virus seroconversion among young injection drug
4 users: relationships and risks. *J Infect Dis* **2002**; 186: 1558–64.
5
6
7
8
9 [11] Maher L, Jalaludin B, Chant KG et al. Incidence and risk factors for hepatitis C seroconversion in
10 injecting drug users in Australia. *Addiction* **2006**; 101(10): 1499-1508.
11
12
13
14 [12] Maher L, Li J, Jalaludin B et al. High hepatitis C incidence in new injecting drug users: a policy
15 failure? *Aust N Z J Public Health* **2007**; 31(1): 30-35.
16
17
18
19 [13] Patrick DM, Tyndall MW, Cornelisse PG et al. Incidence of hepatitis C virus infection among drug
20 users during an outbreak of HIV infection. *Can Med Assoc J* **2001**; 165: 889–95.
21
22
23
24 [14] Miller CL, Johnston C, Spittal PM et al. Opportunities for prevention: hepatitis C prevalence and
25 incidence in a cohort of young injection drug users. *Hepatology* **2002**; 36: 737–42.
26
27
28
29 [15] Davis M, Rhodes T. Beyond prevention? *International Journal of Drug Policy* **2004**; 15:123-31.
30
31
32
33 [16] National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually
34 transmissible infections in Australia. Annual Surveillance Report 2009. National Centre in HIV
35 Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW.
36
37
38
39 [17] NCHECR. Hepatitis C Virus Projections Working Group, Sydney: NCHECR, **2006**.
40
41
42 [18] Kwiatkowski CF, Fortiun Corsi K, Booth RE. The association between knowledge of hepatitis C virus
43 status and risk behaviors in injection drug user. *Addiction* **2002**; 97:1289-94.
44
45
46
47 [19] Gerlach J, Diepolder H, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and
48 treatment-induced viral clearance. *Gastroenterology* **2003**; 125:80-8;
49
50
51
52 [20] Kamal SM, Fouly AE, Kamel RR et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of
53 onset of therapy on sustained virologic response. *Gastroenterology* **2006**; 130:632-638;
54
55
56
57
58
59
60

1
2
3 [21] Gregory JD, Hellard M, Matthews GV, et al. Effective Treatment of Injecting Drug Users with
4 recently acquired hepatitis C virus infection. *Gastroenterology* **2010**; 138:123-135;
5
6

7
8
9 [22] Topp L, Iversen, J, Wand H, Day C, Kaldor J, Maher L. Representativeness of injecting drug users who
10 participate in HIV surveillance: results from Australia's Needle and Syringe Program Survey. *J Acquir*
11 *Immune Defic Syndr* **2008**; 47(5), 632-638.
12
13

14
15
16 [23] MacDonald M, Crofts N, Kaldor J Transmission of hepatitis C virus: rates, routes, and cofactors.
17 *Epidemiol Rev* **1996**; 18(2), 137-148.
18
19

20
21
22 [24] MacDonald M, Wodak AD, Ali R et al. HIV prevalence and risk behavior in needle exchange
23 attenders: a national study. The Collaboration of Australian Needle Exchanges. *Med J Aust* **1997**;
24 166(5),237-240.
25
26

27
28
29 [25] MacDonald MA, Wodak AD, Dolan KA et al. Hepatitis C virus antibody prevalence among injecting
30 drug users at selected needle and syringe programs in Australia, 1995-1997. Collaboration of Australian
31 NSPs. *Med J Aust* **2000**; 172(2),57-61.
32
33

34
35
36 [26] Schmidt MI, Duncan BB, Bang H et al. Identifying individuals at high risk for diabetes: the
37 Atherosclerosis Risk in Communities study. *Diabetes Care* **2005**; 28:2013-2018.
38
39

40
41
42 [27] Gonen M. Analyzing Receiver Operating Characteristic Curves with SAS **2007**. Cary, NC: SAS
43 Institute;
44

45
46
47 [28] Sackett D, Straus SE, Richardson WS, Rosenberg W, Haynes B. Evidence- Based Medicine: How to
48 Practice and Teach EBM. 2nd ed. Philadelphia: Churchill Livingstone; **2000**.
49

50
51
52 [29] Wand H, Spiegelman D, Law M, Kaldor J, Maher Lisa. Estimating population attributable risk for
53 hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and
54 planning. *Addiction* **2009**, 104(12), 2049-2056(8).
55
56
57
58
59
60

1
2
3 [30] Maher L, Iversen J, Kaldor J. Measuring effectiveness of needle and syringe exchange programs for
4 prevention of HIV among injecting drug users: Response to Amundsen. *Addiction* **2006**; 101(12):1834-6.
5
6
7

8
9 [31] Volk M, Tocco R, Saini S, Lok A. Public health impact of antiviral therapy for hepatitis C in the United
10 States. *Hepatology* **2009**;50:1-6
11
12

13
14 [32] White B, Day C, Maher L. Self reported risk behavior among injecting drug users: Self versus assisted
15 questionnaire completion. *AIDS Care* **2007**; 19(3): 441-447.
16
17

18
19 [32] Vickers AJ, Basch E, Kattan MW. Against diagnosis. *Ann Intern Med.* **2008**; 149:200-3. [PMID:
20 18678847]
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Risk factors for Hepatitis C Virus (HCV)

Characteristics	HCV Seronegative N= 5,214 (49%)	HCV Seropositive N= 5,448 (51%)
Mean age at survey (\pm SD)	29 \pm 8	34 \pm 9
<25 years, %	35	16
25-29 years, %	24	19
30-39 years, %	29	37
40+ years, %	12	28
Female, %	33	35
Indigenous, %	8	10
Mean age at first injection (\pm SD)	20 \pm 6	19 \pm 6
Mean years of injecting (\pm SD)	9 \pm 7	15 \pm 9
<5 years, %	26	12
5-9 years, %	28	21
10-16 years, %	23	28
17+ years, %	14	40
Ever been in Prison, %	17	33
Been in prison last year, %	11	22
Drug injecting behaviors (last month)		
Drug injected, %		
Amphetamine/methamphetamine	51	28
Heroin	35	48
Cocaine	3	5
Methadone	4	8
Morphine	7	9
Buprenorphine	1	2
Others ¹	9	8
Injecting daily or more, %	50	58
Receptive sharing needle/syringe, %	15	18
Receptive sharing ancillary equipments ² , %	33	38
Injected by another, %	14	12
New needle syringe in every injection	72	68
Injected in Public	46	52

¹benzos, anabolic steroids, mixed drugs, other drugs or not reported

²water, spoon, filter, tourniquet

Table 2: Multivariate logistic regression: Odds Ratios (OR) and 95% confidence intervals (CI) for HCV infection Scoring by age groups

	<25			25-29			30-39			40+		
	OR (P)	β^*10	Score	OR (P)	β^*10	Score	OR (P)	β^*10	Score	OR (P)	β^*10	Score
Sex												
Male	1	-	0	1			1			-		
Female	1.4	3.4	3	1.5 (<0.001)	4.1	4	1.4 (0.002)	3.3	3			
Indigenous												
No	-	-	-	-	-	-	1	-	-			
Yes							1.3 (0.04)	2.8	3			
Ever been in Prison?												
No	1	1	0	1			1			1		
Yes	2.2 (<0.001)	7.8	8	2.8 (<0.001)	10.2	10	1.9 (<0.001)	6.4	6	1.4 (0.003)	3.4	3
Years of injecting												
<5 year	1	-	0	1						1		
5-9 years	2.0 (<0.001)	6.8	7	1.7 (<0.001)	5.5	6	1.9 (<0.001)	6.5	7	1.5 (0.149)	3.7	4
10+ years	3.1 (<0.001)	11.1	11	2.4 (<0.001)	8.9	9	3.6 (<0.001)	12.7	13	4.6 (<0.001)	15.3	15
Drug last injected												
Amphetamine/methamphetamine	1	-	0	1			1	-	-	1		
Morphine	2.3 (<0.001)	8.3	8	1.7 (0.009)	5.5	6	1.9 (<0.001)	6.7	7	1.9 (<0.001)	6.7	7
Others ²	2.0 (<0.001)	6.7	7	1.6 (0.010)	4.7	5	1.8 (<0.001)	5.9	6	1.5 (0.053)	4.0	4
Heroin	3.0 (<0.001)	11.1	11	2.7 (<0.001)	10.0	10	3.0 (<0.001)	10.7	11	2.5 (<0.001)	9.0	9
Cocaine	6.4 (<0.001)	18.6	19	3.6 (<0.001)	12.7	13	3.0 (<0.001)	10.9	11	3.6 (<0.001)	12.8	13
Methadone	3.3 (<0.001)	11.3	11	3.4 (<0.001)	12.2	12	3.0 (<0.001)	11.0	11	3.1 (<0.001)	11.3	11
Buprenorphine	3.2 (0.003)	11.4	11	2.8 (0.004)	10.4	10	2.8 (0.001)	10.2	10	1.9 (0.141)	6.2	6
(Drug injecting behaviors last month)												
Injecting frequency												
Less than daily	1	-	0	1								
Daily or more	1.4 (0.001)	3.1	3	1.5 (<0.001)	4.0	4	-	-	-	-	-	-
Receptive sharing needle/syringe												
No	-	-	-	1			1	-	-	-	-	-
Yes	-	-	-	1.4 (0.005)	3.4	3	1.4 (0.002)	3.3	3			
Receptive sharing ancillary equipment²												
No	1	1	0	1						1		
Yes	1.3 (0.006)	2.5	3	1.3 (0.003)	3.0	3	-	-	-	1.5 (0.001)	3.8	4

¹benzos, anabolic steroids, mixed drugs, other drugs or not reported

²water, spoon, filter, tourniquet

Table 3: Odds Ratios (OR) and 95% confidence intervals (CI) & for HCV infection by quintiles of HCV scoring

	Age <25 years		Age 25-29 years		Age 30-39 years		Age 40 plus	
Development Data Set	OR (95% CI)	P ⁰	OR (95% CI)	P ⁰	OR (95% CI)	P ⁰	OR (95% CI)	P ⁰
HCV Risk score ¹		<0.001		<0.001		<0.001		<0.001
Fifth 1	1		1		1		1	
Fifth 2	1.90 (1.33,2.69)		2.60 (1.88,3.57)		2.23 (1.72,2.89)		2.63 (1.94,3.58)	
Fifth 3	2.77 (1.92,4.01)		4.12 (3.00, 5.65)		4.07 (3.13,5.28)		4.56 (3.10,6.70)	
Fifth 4	5.40 (3.95,7.38)		4.85 (3.53,6.66)		5.40 (4.16,7.02)		5.86 (4.25,8.08)	
Fifth 5	10.31 (7.44,14.29)		12.40 (9.08,16.91)		9.10 (7.04,11.75)		7.78 (5.61,10.80)	
Population attributable risk for HCV score (%) ² (95% CI)								
lowest v upper four fifth	78% (75%, 81%)		82% (80%, 84%)		80% (78%, 82%)		80% (77%, 82%)	
lower two v upper three fifth	74% (72%, 77%)		76% (74%, 78%)		74% (73%, 77%)		72% (69%, 74%)	
Validation Data Set								
HCV Risk score ¹		<0.001		<0.001		<0.001		<0.001
Fifth 1	1		1		1		1	
Fifth 2	1.92 (1.12,3.28)		2.75 (1.73,4.38)		2.73 (1.94,3.85)		1.98 (1.30,3.02)	
Fifth 3	4.70 (2.75,8.04)		4.33 (2.78,6.77)		5.34 (3.74,7.63)		5.03 (2.78,9.10)	
Fifth 4	6.00 (3.76,9.56)		6.13 (3.93,9.56)		7.46 (5.19,10.74)		3.79 (2.44,5.87)	
Fifth 5	11.97 (7.41,19.32)		9.28 (6.07,14.19)		10.68 (7.56,15.10)		5.42 (3.50,8.42)	
Population attributable risk for HCV score (%) ² (95% CI)								
lowest v upper four fifth	82% (79%, 85%)		80% (77%, 83%)		84% (82%, 85%)		73% (68%, 77%)	
lower two v upper three fifth	79% (76%, 81%)		74% (71%, 77%)		78% (76%, 79%)		67% (62%, 71%)	

⁰ Test for trend

¹ HCV score for age <25 was <7 for fifth 1, 7-<14 for fifth 2, 14-<17 for fifth 3, 17-<24 for fifth 4 and 24+ for fifth 5; for age 25-29 was <12 for fifth 1, 12-<17 for fifth 2, 17-<22 for fifth 3, 22-<26 for fifth 4 and 24+ for fifth 5; for age 30-39 was <13 for fifth 1, 13-<19 for fifth 2, 19-<24 for fifth 3, 24-<27 for fifth 4 and 27+ for fifth 5; for age 40 plus was <15 for fifth 1, 15-<22 for fifth 2, 22-<24 for fifth 3, 24-<27 for fifth 4 and 27+ for fifth 5;

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Table 4: Optimal characteristics of HCV Scoring¹

	Age <25 years		Age 25-29 years		Age 30-39 years		Age 40 plus	
Score cut points ²	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity
Development Data Set (n=10,662)								
10 ≥ 10	96%	17%	99%	9%	99%	7%	98%	10%
11 ≥ 15	92%	32%	95%	23%	97%	15%	97%	19%
12 ≥ 20	74%	60%	86%	42%	90%	36%	94%	24%
13 ≥ 25	55%	74%	68%	64%	73%	57%	75%	54%
Validation Data Set (n= 5,465)								
16 ≥ 10	96%	18%	99%	8%	99%	10%	99%	10%
17 ≥ 15	94%	32%	95%	25%	97%	19%	97%	15%
18 ≥ 20	76%	57%	88%	40%	87%	43%	94%	21%
19 ≥ 25	59%	72%	67%	61%	73%	61%	74%	52%

¹HCV Score :

For age < 25: (female)*3+ (indigenous) *0 + (Injecting 5-9 years)*7 + (Injecting 10+ years) *11+ Morphine*8 + (other drugs e.g. benzos, anabolic steroids, mixed drugs, other drugs)*7 + (heroin)*11 + (cocaine)*19 + (methadone)*11 + (morphine)*8 + (Buprenorphine) *11 + (daily or more)*3 + (shared needle and syringe)*0 + (shared other equipment)*3 + (been in prison)*8

For age 25 -29 year: (female)*4+ (indigenous) *0 + (Injecting 5-9 years)*6 + (Injecting 10+ years) *9+ Morphine*6 + (other drugs e.g. benzos, anabolic steroids, mixed drugs, other drugs)*5 + (heroin)*10 + (cocaine)*13 + (methadone)*12 + (morphine)*5 + (Buprenorphine) *10 + (daily or more)*4 + (shared needle and syringe)*4 + (shared other equipment)*0 + (been in prison)*6

For age 30 -39 year: (female)*3+ (indigenous) *3 + (Injecting 5-9 years)*7 + (Injecting 10+ years) *13+ Morphine*7 + (other drugs e.g. benzos, anabolic steroids, mixed drugs, other drugs)*6 + (heroin)*11 + (cocaine)*11 + (methadone)*11 + (morphine)*7+ (Buprenorphine) *10 + (daily or more)*0 + (shared needle and syringe)*3 + (shared other equipment)*0 + (been in prison)*6


For age 40 + year: (female)*0+ (indigenous) *0 + (Injecting 5-9 years)*4 + (Injecting 10+ years) *15 + Morphine*7 + (other drugs e.g. benzos, anabolic steroids, mixed drugs, other drugs)*4 + (heroin)*9 + (cocaine)*13 + (methadone)*11 + (morphine)*7+ (Buprenorphine) *6 + (daily or more)*0 + (shared needle and syringe)*3 + (shared other equipment)*0 + (been in prison)*6

²Approximate cut points for the first, second, third and the fourth quintiles.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Total score versus risk of HCV infection





Developing and validating a scoring tool for identifying people who inject drugs at increased risk of hepatitis C virus infection

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000387.R1
Article Type:	Research
Date Submitted by the Author:	11-Oct-2011
Complete List of Authors:	Wand, Handan; University of New South wales Iversen, Jenny; The Kirby Institute Wilson, David; The Kirby Institute Topp, Libby; The Kirby Institute Maher, Lisa; The Kirby Institute
Primary Subject Heading :	Epidemiology
Secondary Subject Heading:	Infectious diseases
Keywords:	INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES, Infection control < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts

RESPONSE TO REVIEWER'S COMMENTS: MANUSCRIPT ID BMJOPEN-2011-000387

Reviewer #1: Natasha Martin, University of Bristol, UK. I have no conflicts of interest.

Reviewer comment #1.1: *This is an important study which develops and validates a scoring tool to assess HCV risk among PWID, with the aim of facilitating increased screening. The paper is strengthened by the large data set (16,000 PWID), which allowed for the use of development and validation data sets. Given the low rates of testing and treatment in this population, a tool such as this could be of value to identifying those who would benefit from increased testing. As such, I believe this paper should be published in BMJ Open.*

My only minor comment surrounds the use of the tool. In the abstract the authors state that "risk assessment strategies may assist to alert PWID who are at increased risk of HCV infection to present for testing." However the discussion centres more on the use of the tool to "inform the establishment of more focused national screening guidelines." Can the authors please discuss the importance of self-assessment and presentation for testing in the discussion? Additionally, can the authors clarify what they mean by 'more focused national screening guidelines'? Do they feel that screening should be focussed only on 'high-risk' PWID identified by the tool, or if these individuals should be targeted for increased screening-- over and above a comprehensive PWID screening program?

Author's response #1.1: We would like to thank to the reviewer for her positive and constructive comments. We have clarified the potential use of the tool and what we mean by "more focused screening guidelines", as well as discussing the importance of self-assessment and presentation for testing. We revised the relevant section as follows:

(Please also see DISCUSSION, page 9):

1
2
3 “Current Australian guidelines recommend HCV antibody screening in all individuals with risk factors
4 for infection regardless of patient characteristics and settings [30]. Increasing the rate of HCV
5 diagnosis and, in particular, diagnosis of acute infection and providing access to effective antiviral
6 treatment has the potential to improve individual quality of life and reduce the burden of HCV
7 infection. Being unaware of one’s HCV serostatus has been identified as a major barrier to increasing
8 HCV treatment uptake, including among PWID [31,32]. While a relatively high proportion (64%) of
9 participants in the ANSPS reported recent HCV testing, HCV antibody negative respondents were less
10 likely to do so than antibody positive respondents (60% versus 67%). One in five (20%) HCV antibody
11 negative participants had not been tested for HCV in the last twelve months, and a further 20% had
12 never been tested (www.web.med.unsw.edu.au/nchecr/Publications). This suggests that both uptake
13 and frequency of testing could be improved.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 (Please also see page 10, 2nd and 3rd paragraphs):
34

35 “Although Australia has screening guidelines for hepatitis C, current guidelines do not target specific
36 attributes or injecting risk behaviours [30]. By focusing on particular characteristics and specific high-
37 risk behaviours, tools such as the one developed in this study may allow for more targeted
38 identification of individuals at increased risk of infection. If used as a self-administered questionnaire,
39 it is likely that respondents will answer more accurately [33]. Since the vast majority of new HCV
40 diagnoses in Australia are among people with a history of injecting drug use, this tool provides a
41 valuable resource which could inform the establishment of more focused national screening
42 guidelines.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Further, although current clinical practice guidelines recommend HCV screening of individuals with a
4
5 history of injecting drugs, this recommendation focuses on a single risk factor (i.e. injecting drug use)
6
7 whereas considering the cumulative effect of multiple risk factors can more precisely identify people
8
9 in need of additional, non-routine screening. This is particularly pertinent in resource-constrained
10
11 environments (including time-restricted clinical settings). Our methodology made use of a range of
12
13 coexisting risk factors that were identified by a rigorous statistical approach in order to accurately
14
15 identify the most relevant factors for HCV infection.
16
17
18
19
20
21
22

23
24 (Please also see page 12, last paragraph)

25
26 “Self-assessment of individual personal level-risk based on a combination of risk factors may prompt a
27
28 decision to be tested by current injectors, potentially increasing uptake of screening, diagnosis, and
29
30 antiviral treatment in this population. In summary, the tool described here has the potential to
31
32 engage current PWID in timely and accurate risk analysis, potentially modifying risk behaviour, and
33
34 increasing uptake of HCV screening and antiviral treatment in this population.”
35
36
37
38
39
40
41

42 **Reviewer comment #1.2:** *In addition, the authors note that "Although Australia has screening*
43 *guidelines for hepatitis C, current guidelines do not specifically target PWID" but then go on to say*
44 *"although current clinical practice guidelines recommend HCV screening of individuals with a history of*
45 *injecting drugs...". Can the authors please clarify whether the screening guidelines do or do not*
46 *recommend/target PWID for testing?*
47
48
49
50
51
52
53
54

55
56 **Author's response #1.2:** We are grateful to the reviewer for spotting this error. The text on page 9 has
57
58 now been changed to read as follows:
59
60

1
2
3
4 (Please also see DISCUSSION, page 10)
5

6 "Although Australia has screening guidelines for hepatitis C, current guidelines do not target **specific**
7 **attributes or injecting risk behaviours** [30]. **By focusing on particular characteristics and** high-risk
8 **behaviours**, tools such as the one developed in this study may allow for more targeted identification
9 of individuals at increased risk of infection".
10
11
12
13
14

15
16
17
18 This is now consistent with the text which goes on to say (same page, paragraph 2):
19

20
21
22
23 "Further, although current clinical practice guidelines recommend HCV screening of individuals with a
24 history of injecting drugs, this recommendation focuses on a single risk factor (i.e. injecting drug use)
25 whereas considering the cumulative effect of multiple risk factors among PWID can more precisely
26 identify people in need of additional, non-routine screening. This is particularly pertinent in resource
27 constrained environments (including time-restricted clinical settings). Our methodology made use of a
28 range of coexisting risk factors that were identified by a rigorous statistical approach in order to
29 accurately identify the most relevant factors for HCV infection."
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reviewer # 2: Vana Sypsa

Lecturer of Epidemiology and Preventive Medicine Dept. of Hygiene, Epidemiology and Medical Statistics Athens University Medical School Greece

The sample consisted of injecting drug users participating in a needle exchange program. This limitation is acknowledged by the authors.

This paper proposes a tool - based on demographic and injecting risk behavior- to identify injecting drug users at increased risk for HCV. The analysis was based on a large sample of injecting drug users in Australia and a sub-sample was used to validate the scoring system.

Major comments

Reviewer comment #2.1: *Although the authors have done a lot of work in developing and validating this scoring tool, they fail to provide a clear message that would guide decisions based on the use of this tool. The authors mention in the discussion of their paper that "The tool was validated to accurately identify those at increased risk of HCV" and after a few sentences "The intention of this study was not to identify a unique and specific cut-point of risk above which to target screening, but rather, to assess whether risk factors under consideration could predict those at increased risk accurately in order to consider the tool's use in facilitating increased screening". They also mention that as HCV is highly prevalent among injecting drug users in Australia, they should all be screened and that identification of at least one risk factor increased substantially the likelihood of infection. It seems that the authors conclude that if a person reports at least one of these risk factors, then he/she has to be screened. What is the utility of the score then? The discussion should be re-organized in this*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

aspect in order to provide a clearer message on how this screening tool can be used. You mention that the scoring system was also validated using prospective data. Are these results included in the paper?

Author's response #2.1:

We would like to thank to the reviewer for raising this valid point. The most important contribution of this study is in determining the combined impact of the risk factors in relation to risk of HCV. We agree that the use of "tool" was not clearly described. We have now revised the discussion on page 10 as follows:

"The tool was validated to **more** accurately identify those at increased risk of HCV infection. Current Australian guidelines recommend HCV antibody screening in all individuals with risk factors for infection regardless of patient characteristics and settings [30]. Increasing the rate of HCV diagnosis and, in particular, diagnosis of acute infection and providing access to effective antiviral treatment has the potential to improve individual quality of life and reduce the burden of HCV infection. **Being unaware of one's HCV serostatus has been identified as a major barrier to increasing HCV treatment uptake, including among PWID [31,32].** While a relatively high proportion (64%) of participants in the ANSPS reported recent HCV testing, HCV antibody negative respondents were less likely to do so than antibody positive respondents (60% versus 67%). One in five (20%) HCV antibody negative participants had not been tested for HCV in the last twelve months, and a further 20% had never been tested (www.web.med.unsw.edu.au/nchecr/Publications). This suggests that both uptake and frequency of testing could be improved.

1
2
3 The intention of this study was not to identify a unique and specific cut-point of risk above which to
4 target screening, but rather, to assess whether risk factors under consideration could predict those at
5 increased risk accurately in order to consider the tool's use in facilitating increased screening. With a
6 high background HCV prevalence of ~70% among Australian PWID, all PWID should be screened for
7 HCV. However, identification of only one of our listed risk factors substantially increased the
8 likelihood of infection. Although Australia has screening guidelines for hepatitis C, current guidelines
9 do not target **specific attributes or injecting risk behaviours** [30]. By focusing on **particular**
10 **characteristics and** high-risk behaviours, tools such as the one developed in this study may allow for
11 more targeted identification of individuals at increased risk of infection. If used as a self-administered
12 questionnaire, it is likely that respondents will answer more accurately [33]. Since the vast majority of
13 new HCV diagnoses in Australia are among people with a history of injecting drug use, this tool
14 provides a valuable resource which could inform the establishment of more focused national
15 screening guidelines.

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38 Further, although current clinical practice guidelines recommend HCV screening of individuals with a
39 history of injecting drugs, this recommendation focuses on a single risk factor (i.e. injecting drug use)
40 whereas considering the cumulative effect of multiple risk factors can more precisely identify people
41 in need of additional, non-routine screening. This is particularly pertinent in resource constrained
42 environments (including time-restricted clinical settings). Our methodology made use of a range of
43 coexisting risk factors that were identified by a rigorous statistical approach in order to accurately
44 identify the most relevant factors for HCV infection.

45
46
47
48
49
50
51
52
53
54
55
56
57
58 (Please also see page 12, last paragraph)
59
60

“Self-assessment of individual personal level-risk based on a combination of risk factors may prompt a decision to be tested by current injectors, potentially increasing uptake of screening, diagnosis, and antiviral treatment in this population. In summary, the tool described here has the potential to engage current PWID in timely and accurate risk analysis, potentially modifying risk behaviour, and increasing uptake of HCV screening and antiviral treatment in this population.”

Reviewer comment #2.2: *You mention that the scoring system was also validated using prospective data. Are these results included in the paper?*

Author’s response #2.2: We have performed this validation using data from a prospective study [3] we did not include these results in the current study. Below, we present these results (Table A and Figure A) for the reviewer. If the editors deem necessary we would also be happy to include these results in the revised manuscript. We have also edited the relevant sentence as follows:


(Please also see on page 11, second paragraph)

“Our study has several strengths, including being the first to validate a predictive model through in internal cross sectional and prospective data sets (data not shown).”

Table A: Results from prospective data

Risk factors, No.	Validation Data set Prospective	
	HR (95% CI)	P Value
2 or less	Reference	
3	1.10 (0.74, 1.60)	0.667
4	1.15 (0.78, 1.65)	0.504
5	2.17 (1.45, 3.17)	<0.001
6 or more	3.19 (2.30, 5.51)	<0.001

Figure A: Sensitivity/Specificity for the prospective validation:



Minor comments

Reviewer comment #2.3: Abstract (objective): "To develop and validate" instead of "To develop and a validate"

Author's response #2.3: Done.

Reviewer comment #2.4: *Abstract (methods): More appropriate terms for "univariate" and "multivariate" are "univariable" and "multivariable" (as you refer to the number of independent variables in your model) (see also Hosmer & Lemeshow, Applied Logistic Regression, Wiley, 2000).*

Author's response # 2.4: Done.

Reviewer comment #2.5: *Abstract (line 4 of results): The age grouping should be added.*

Author's response # 2.5: In response to this reviewer's comments we have included age groups in the abstract as follows:

"An estimated 78% (95% CI: 75%, 81%), 82% (95% CI: 80%, 84%), 80% (95% CI: 78%, 82%) and 80% (95% CI: 77%, 82%) of HCV infections across the age groups (<25, 25-29, 30-39 and 40 or older) would be avoided if participants in the upper four quintiles of HCV scores fell instead into the lowest quintile."

1
2
3
4 **Reviewer comment #2.6:** *Abstract (last line of results): This sentence is not clear. It is more clearly*
5 *written in the main body of the paper i.e. "fell in the lowest quintile" instead of "had reduced risk to*
6 *be in the lowest quintile of HCV scores".*

9
10 **Author's response #2.6:** Following the reviewer's comments we edited the relevant sentence as
11 follows:

12
13
14 "An estimated 78% (95% CI: 75%, 81%), 82% (95% CI: 80%, 84%), 80% (95% CI: 78%, 82%) and 80%
15 (95% CI: 77%, 82%) of HCV infections across the age groups (<25, 25-29, 30-39 and 40 or older) would
16
17 be avoided if participants in the upper four quintiles of HCV scores fell instead into the lowest
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
quintile. "

27 **Reviewer comment #2.7:** Abstract (conclusion). The abbreviation PWID should be explained in the
28 abstract.

31 **Author's response #2.7:** Done.

34 **Reviewer comment #8:** *Page 4, Study population: Is there an estimate of the participation rate? (i.e.*
35 *on how many consented to complete the questionnaire and provide blood sample). Did you obtain*
36 *written informed consent? Did the study require ethics approval?*

41 **Author's response #2.8:** Due to the illicit behaviour of participants, no identifying information is
42 collected by the study and verbal informed consent is obtained from participants. The response rate
43 ranged from 38% to 50% over the period 1998 to 2008. Ethical approval was obtained from the
44 Human Research Ethics Committee (HREC) at the University of New South Wales, along with relevant
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
jurisdictional and site-specific HRECs.

This was mentioned on page 4 (second paragraph) as follows:

1
2
3 “Following provision of verbal informed consent to participate, respondents were asked to complete
4
5 a brief,…”
6

7
8 This was mentioned on page 5 (second paragraph) as follows:
9

10 “Ethical approval was obtained from the Human Research Ethics Committee (HREC) at the University
11
12 of New South Wales, as well as from relevant jurisdictional and site specific HRECs.”
13

14
15
16
17 **Reviewer comment #2.9:** *Discussion, page 9, In 41-44. Is this true for injecting drug users too?*

18
19
20 **Author’s response #2.9:** We thank the reviewer for drawing this to our attention. We did not mean
21
22 to infer that being unaware of one’s HCV serostatus was the major barrier to increasing treatment
23
24 uptake in PWID. While being unaware of one’s serostatus is also a barrier to treatment uptake in this
25
26 group, several studies have identified a number of barriers specific to PWID and we have now
27
28 included a citation [32] to a review of barriers specific to this group.
29

30 We have revised this sentence as follows:

31
32 (Please also see DISCUSSION, page 9)

33
34
35 “Being unaware of one’s HCV serostatus has been identified as a major barrier to increasing HCV
36
37 treatment uptake, including among PWID [31,32].”
38
39

40
41 **Reviewer comment #2.10:** *Page 18. Last reference is number 33.*

42
43
44 **Author’s response #2.10:** Since we have added another reference ([32] Edlin BR et al.), last reference
45
46 number is 34 now.
47

48
49
50 **Reviewer comment #2.11:** *Table 2. It would be useful to include an extra line with the number of*
51
52 *persons (N=...) under the line with the age-group headings.*
53

54
55 **Author’s response #2.11:** Following the reviewer’s comment we added an extra line with the number
56
57 of persons in each age category in Table 2 (please also see below)
58
59
60

Table 2: Multivariable logistic regression: Odds Ratios (OR) and 95% confidence intervals (CI) for HCV infection scoring by age groups

	<25 N=2,686			25-29 N=2,291			30-39 N=3,563			40+ N=2,122		
	OR (P)	β^*10	Score	OR (P)	β^*10	Score	OR (P)	β^*10	Score	OR (P)	β^*10	Score

Reviewer comment #2.12: *The authors do not mention whether they obtained a written informed consent or if the study required ethics approval.*

Author’s response #2.12: Ethical approval is noted on page 5, second full paragraph (please also see below):

“Ethical approval was obtained from the Human Research Ethics Committee (HREC) at the University of New South Wales, as well as from relevant jurisdictional and site specific HRECs.”

1
2
3
4
5
6
7 **Developing and validating a scoring tool for identifying people who inject drugs at**
8 **increased risk of hepatitis C virus infection**
9

10
11
12
13
14
15
16 Handan Wand, Jenny Iversen, David Wilson, Libby Topp and Lisa Maher

17
18
19 The Kirby Institute, Sydney, Australia, University of New South Wales

20
21
22 October 11, 2011

23
24
25
26 Revised

27
28
29 **Corresponding author:**

30
31
32 Handan Wand, PhD

33
34
35 The Kirby Institute, University of New South Wales, Sydney, Australia

36 Telephone: +61-2-9385 0900

37 Facsimile: +61-2-9385 0920

38 Email: hwand@nchechr.unsw.edu.au
39
40
41
42
43

44 Word counts:

45
46 Abstract: 206

47
48 Manuscript: 2,693
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Objective:** To develop and validate a scoring tool based on demographic and injecting risk behaviors
4
5 to identify those who require additional, non-routine serological screening for HCV by assessing their
6
7 personal risk.
8
9

10
11 **Methods:** The analysis included 16,127 participants who attended Needle and Syringe Programs (NSP)
12
13 in Australia (1998-2008). **Univariable and multivariable** logistic regression models were used to
14
15 develop a prediction model by age groups.
16
17

18
19 **Results:** Type of drug last injected, frequency and duration of injecting, sharing needles and syringes
20
21 or other injecting equipment and imprisonment history were associated with HCV infection in all age
22
23 groups. Strong relationships between an individual's 'HCV score' and their risk of testing HCV antibody
24
25 positive were observed. **An estimated 78% (95% CI: 75%, 81%), 82% (95% CI: 80%, 84%), 80% (95% CI:**
26
27 **78%, 82%) and 80% (95% CI: 77%, 82%) of HCV infections across the age groups (<25, 25-29, 30-39**
28
29 **and 40 or older) would be avoided** if participants in the upper four quintiles of HCV scores fell instead
30
31 into the lowest quintile.
32
33
34
35

36
37 **Conclusion:** Knowledge of HCV status has important implications for public health and care and
38
39 treatment. Risk assessment strategies may assist in alerting **people who inject drugs** (PWID) who are
40
41 at increased risk of HCV infection to present for testing.
42
43
44
45

46
47
48
49 **Key words:** Hepatitis C infection, injecting drug users, risk assessment
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Worldwide, infection with hepatitis C virus (HCV) is common among people who inject drugs (PWID) [1]. Estimates suggest that more than 70% of new cases of HCV infection are associated with injecting drug use [2,3]. Epidemiologic studies have identified independent risk factors for HCV infection, including sharing of contaminated needles and syringes [4-7] and other injecting equipment [8, 9], female gender [10,11], duration of injecting [12] and intravenous cocaine use [13, 14]. Although the risk factors for incident infection are well established, the literature suggests that a number of barriers may prevent PWID presenting for screening and many PWID face the possibility of HCV infection with a sense of inevitability, fostered by structural barriers to risk avoidance [15, 16]. PWID are a priority population in Australia as HCV prevalence remains high in this group. The burden of advanced liver disease (liver failure and hepatocellular carcinoma) continues to grow among HCV-infected people [17]. It is estimated that 5,300 Australians are living with HCV-related cirrhosis and this figure is expected to double by 2020 without increased therapeutic intervention [18]. Despite the mounting burden of disease and recent advances in antiviral treatments, HCV treatment uptake among PWID remains very low (1-2% of chronic hepatitis C cases) [17]. A major public health challenge is to more effectively identify individuals with HCV before the development of significant clinical consequences.

Our study aimed to develop a scoring tool that can be used by PWID and primary care providers to identify individuals at increased risk of HCV infection. With increasing recognition of the clinical benefits of early diagnosis and treatment uptake [19-21], a simple self-administered tool may provide a means for PWID to identify personal risk and to modify risk behavior and/or seek health care/further assessment.

1
2
3 A large database of serial cross sectional samples of PWID attending Needle and Syringe Programs
4 (NSP) in Australia (1998-2008) was used to develop a statistical model underpinning the tool.
5
6
7 Retrospective validation was carried out on the HCV risk assessment algorithm.
8
9

10
11 The following characteristics were considered essential in the development of the new prediction
12 algorithm: (1) the use of routinely available and minimally intrusive variables and (2) estimation of the
13 cumulative effect of concurrent risk factors on the likelihood of HCV prevalence. We are unaware of
14 any studies to date that have quantified the cumulative effect of concurrent risk factors on the
15 acquisition of HCV infection among PWID.
16
17
18
19
20
21
22
23
24

25 **STUDY POPULATION**

26
27
28 The Australian Needle and Syringe Program Survey (ANSPS) is a serial cross-sectional study conducted
29 annually over a one to two week period since 1995. More than 50 NSP sites participate annually, with
30 sites selected on the basis of geographic coverage, willingness to participate and an ability to recruit a
31 minimum of 20 survey respondents. The survey methods have been described in detail elsewhere [22-
32 25]. In brief, all PWID who attended participating ANSPS sites during the designated survey period
33 were invited to participate. Participation was anonymous and voluntary and there was no financial
34 reimbursement. **Following provision of verbal informed consent to participate, respondents were**
35 **asked to complete a brief**, self-administered questionnaire on demographic characteristics and
36 injecting and sexual risk behaviors (www.web.med.unsw.edu.au/nchecr), and to provide a capillary
37 blood sample for antibody HIV and HCV testing. The current study used data for the period 1998-
38 2008, involving more than 16,000 individuals. **Response rates ranged from 38%-50% during the study**
39 **period (cite the 16 year report). Previous research has demonstrated the representativeness of**
40 **ANSPS samples of the broader population of NSP clients [22].**
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Capillary blood was obtained by finger prick using single-use, disposable lancets and cotton-fiber blotting paper. Specimens were kept at room temperature at the survey sites, then couriered to a central collection point before they were forwarded to the laboratory. A modified, third generation enzyme immunoassay (Abbott hepatitis C 3.0, Chicago, IL, USA) was used to test for HCV antibody. A modified cutoff value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cutoff ratio was greater than or equal to one on initial and subsequent testing.

Ethical approval was obtained from the Human Research Ethics Committee (HREC) at the University of New South Wales, as well as from relevant jurisdictional and site specific HRECs.

STATISTICAL ANALYSES

A split-sample method was used to develop and subsequently validate a risk equation and scoring system. Participants were randomly allocated to either the development (n=10,662; 67%) or internal validation (n=5,331; 33%) sample datasets.

We selected a range of demographic and injecting behavior variables as potential determinants of HCV infection. These included gender, Indigenous status, imprisonment history, country of birth, language spoken at home, drug last injected, frequency and duration of injecting, sharing of needles and syringes and other injecting equipment (e.g. water, filter, spoon, tourniquet), public injecting, and drug treatment history. All analyses were stratified by age groups (<25, 25-29, 30-39 and 40+).

We used descriptive statistics to characterize the groups according to antibody HCV serostatus: mean and standard deviation (SD) for continuous variables and percentages for categorical variables.

Logistic regression was used to create a predictive model based on the development data set. We

1
2
3 used all non-missing observations available in the relevant analyses as only a small proportion of
4
5 observations had any missing data (except for the variable “imprisonment history”). All analyses were
6
7 conducted using SAS statistical software version 9.2 (SAS Institute Inc. Cary, North Carolina) and
8
9 STATA 10.0 (College Station, Texas).
10
11

12 13 **Derivation of a screening score:**

14
15 Using the development data set (n=10,662), we included a comprehensive list of predictors known to
16
17 be associated with HCV antibody seropositivity in an initial model. Specifically, we included the main
18
19 effects of all variables listed in Table 1 and their interaction effects. We first analyzed the univariate
20
21 associations between the independent variables and HCV seropositivity. Backward elimination was
22
23 used to reach the final multivariate model, in which factors with the largest *P* value were sequentially
24
25 deleted until only significant predictors remained. We then created a weighted scoring system by
26
27 rounding all regression coefficients up to the nearest integer (that is, the smallest integer greater than
28
29 the estimate). This method was based on the β -coefficients (or log of the odds ratios) rather than
30
31 odds ratios, which can be excessively influenced by only a few factors [26]. Once the final model was
32
33 defined, we created integer weights for each variable. We calculated these weights by multiplying the
34
35 model coefficients by 10. Using the rounded weights in the risk function, we estimated the
36
37 participant-specific probabilities of HCV seropositivity and characterized the degrees of risk based on
38
39 cut-off points of the probability distribution.
40
41
42
43
44
45
46
47

48 49 **Cross-sectional and prospective validation:**

50
51 We examined the predictive validity of the scoring system using the internal validation datasets
52
53 (n=5,331). We also assessed the predictive validity of this scoring system on the subsequent risk of
54
55
56
57
58
59
60

1
2
3 HCV antibody seroconversion using prospective data collected from individuals who visited ANSPS
4
5 sites multiple times and tested HCV seronegative at their first visit.
6
7

8
9 We used the cross-sectional dataset to check the sensitivity and robustness of the new screening
10
11 score. We computed standard validation measures: the proportion of antibody HCV seropositive
12
13 specimens, sensitivity, specificity, positive likelihood and negative likelihood ratio and the area under
14
15 the receiver operating characteristic curve (AUC) as discrimination statistics. We also assessed the
16
17 diagnostic characteristics of different cut-points based on the total score in the development as well
18
19 as validation datasets. The purpose of this analysis was to assess whether the combination of risk
20
21 factors under consideration could predict those at increased risk with acceptable accuracy.
22
23
24
25

26 27 **Population attributable risk:**

28
29
30 After we calculated and validated the HCV screening score, we estimated population attributable
31
32 risks, which estimates the percentage of HCV infections that would not have occurred if all
33
34 participants had been assigned the “lowest risk” (first quintile) category of the HCV screening score.
35
36 We calculated population attributable risks using a previously described method [29] that was applied
37
38 to this study design and appropriate for use with multivariable adjusted relative risks.
39
40
41
42
43
44

45 **RESULTS**

46
47 Our study population comprised 10,662 individuals in the development dataset. Table 1 summarizes
48
49 participant characteristics by HCV antibody serostatus. The overall prevalence of HCV was 51%. HCV
50
51 seropositive participants tended to be older and more likely to report a longer duration of injecting,
52
53 heroin as the drug last injected, a history of imprisonment, daily or more frequent injecting, public
54
55 injecting and sharing needles and syringes and other injecting equipment.
56
57
58
59
60

1
2
3 Table 2 presents the final multivariate logistic regression model derived from the development data
4 set by age groups. History of imprisonment, duration of injecting (5-9, 10+ years), drug last injected
5 (heroin, cocaine, methadone, morphine, buprenorphine and others), needle and syringe sharing and
6 sharing of ancillary equipment were all significantly associated with increased risk of antibody HCV
7 seropositivity across all age groups. Injecting frequency (daily or more) was determined to be a
8 significant risk factor for those aged less than 30 years. Female gender was associated with an
9 increased risk of HCV seroprevalence for those younger than 40 years of age. Indigenous status was a
10 significant predictor for HCV infection among people aged 30-39 years. Drug last injected and
11 duration of injecting each required multiple categories to capture the risk gradient, whereas other risk
12 factors were binary. The risk factors collectively yielded an AUC of 0.73 (95% CI: 0.70, 0.76), 0.72 (95%
13 CI: 0.70, 0.75), 0.73 (95% CI: 0.70, 0.76) and 0.66 (95% CI: 0.64, 0.71) for the age groups <25, 25-29,
14 30-39 and 40 plus (data not shown). There were no significant interactions between injecting risk
15 behaviors and gender across age groups (data not shown).
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 Table 3 shows the odds ratios (ORs) from the logistic regression models and population attributable
37 risks of HCV infection for the quintiles of the risk scores by age groups for the development and
38 validation datasets. There was a linear trend towards increasing HCV infection with increasing score
39 regardless of the age groups in both datasets (trend, p-value<0.001). Using the development dataset,
40 we estimated population attributable risks (95% CI) for the upper four quintiles of the scores. Results
41 showed that 78% (75%, 81%), 82% (80%, 84%) and 80% (77%, 82%) of HCV infections across the age
42 groups would be avoided if participants in the upper four quintiles of the HCV scores instead fell into
43 the lowest quintile. Results from the validation dataset were consistent with those from the
44 development dataset (Table 3).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 We also assessed the diagnostic characteristics of cut-points (according to first, second, third and the
4
5 fourth quintiles in overall population) for total score in the development as well as the validation
6
7 datasets (Table 4). An increased risk of HCV was clearly associated with increasing scores. For
8
9 example, a cut-point score of 10 or higher distinguished a 'increased risk' group with a sensitivity of
10
11 96% or higher; similarly a cut-point 20 or higher yielded at least 92% sensitivity in all age groups in the
12
13 development dataset; in cross sectional validation, sensitivity was estimated to be at least 94% across
14
15 the age groups for the cut-point 10/15 or more and at least 76% for 20 or more.
16
17
18
19

20
21 Figure 1 illustrates the risk of PWID being HCV seropositive as a continuous function of the total score.
22
23 Across all age groups, increasing scores were clearly associated with increased risk of HCV antibody
24
25 positivity.
26
27
28
29

30 DISCUSSION

31
32
33 In this study, we developed a scoring tool based on data from ~16,000 PWID who attended ANSPS
34
35 sites between 1998 and 2008. The tool was validated to more accurately identify those at increased
36
37 risk of HCV infection. Current Australian guidelines recommend HCV antibody screening in all
38
39 individuals with risk factors for infection regardless of patient characteristics and settings [30].
40
41 Increasing the rate of HCV diagnosis and, in particular, diagnosis of acute infection and providing
42
43 access to effective antiviral treatment has the potential to improve individual quality of life and
44
45 reduce the burden of HCV infection. Being unaware of one's HCV serostatus has been identified as a
46
47 major barrier to increasing HCV treatment uptake, including among PWID [31,32]. While a relatively
48
49 high proportion (64%) of participants in the ANSPS reported recent HCV testing, HCV antibody
50
51 negative respondents were less likely to do so than antibody positive respondents (60% versus 67%).
52
53 One in five (20%) HCV antibody negative participants had not been tested for HCV in the last twelve
54
55
56
57
58
59
60

1
2
3 months, and a further 20% had never been tested (www.web.med.unsw.edu.au/nchechr/Publications).

4
5 This suggests that both uptake and frequency of testing could be improved.

6
7
8
9 The intention of this study was not to identify a unique and specific cut-point of risk above which to
10 target screening, but rather, to assess whether risk factors under consideration could predict those at
11 increased risk accurately in order to consider the tool's use in facilitating increased screening. With a
12 high background HCV prevalence of ~70% among Australian PWID, all PWID should be screened for
13 HCV. However, identification of just one of our listed risk factors substantially increased the likelihood
14 of infection. Although Australia has screening guidelines for hepatitis C, current guidelines do not
15 target specific attributes or injecting risk behaviours [30]. By focusing on particular characteristics
16 and specific high-risk behaviors, tools such as the one developed in this study may allow for more
17 targeted identification of individuals at increased risk of infection. If used as a self-administered
18 questionnaire, it is likely that respondents will answer more accurately [33]. Since the vast majority
19 of new HCV diagnoses in Australia are among people with a history of injecting drug use [16], this tool
20 provides a valuable resource which could inform the establishment of more focused national
21 screening guidelines.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 Further, although current clinical practice guidelines recommend HCV screening of individuals with a
43 history of injecting drugs, this recommendation focuses on a single risk factor (i.e. injecting drug use)
44 whereas considering the cumulative effect of multiple risk factors can more precisely identify people
45 in need of additional, non-routine screening. This is particularly pertinent in resource-constrained
46 environments (including time-restricted clinical settings). Our methodology made use of a range of
47 coexisting risk factors that were identified by a rigorous statistical approach in order to accurately
48 identify the most relevant factors for HCV infection.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Risk calculation approaches have been extensively used in decision making about public health and
4
5 clinical care and have even been proposed as an alternative to diagnosis for some diseases [34]. Our
6
7 risk calculation was based on a statistical method that yielded a systematic scoring system for
8
9 carefully selected predictors, guided not only by numerical and scientific evidence but also feasibility
10
11 perspectives. We chose categorized variables which highlighted the important risk factors to
12
13 motivate high-risk persons to be screened or to modify behaviors. This combination of factors may
14
15 explain the enhanced properties of our scoring tool.
16
17
18
19

20
21 Our study has several strengths, including being the first to validate a predictive model through
22
23 internal cross sectional and prospective data sets (data not shown). Our prediction equation is based
24
25 on 11 years of data and more than 16,000 participants. Ideal risk assessment methods or prediction
26
27 models should be derived from large representative samples. The current study has several
28
29 limitations. First, the study population is limited to those who participated in the ANSPS, which may
30
31 result in selection bias. However, the ANSPS has been shown to be broadly representative of PWID
32
33 attending NSPs [16]. Second, we were not able to differentiate between acute, recent and chronic
34
35 infections.
36
37
38
39

40
41 Risk factor screening and identification allows for patients to be educated regarding the risks of
42
43 injection drug use and needle sharing. Appropriate testing and diagnosis of HCV allows for the patient
44
45 to be evaluated for treatment and receive counseling regarding HCV prevention. In addition to
46
47 physician education, patient education campaigns must also be developed to increase patient
48
49 compliance with testing recommendations made by their physicians.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 In conclusion, we believe the screening tool described here will provide a simple and cost-effective
4
5 method of identifying and alerting PWID who are in need of additional, non-routine HCV screening
6
7 with notable predictive validity. A self-assessment method that helps individual PWID understand
8
9 their relative increased risk of infection provides the basis for increased uptake of screening,
10
11 diagnosis, and antiviral treatment among this population.
12
13

14
15
16 In summary, the tool described here has the potential to engage current PWID in timely and accurate
17
18 risk analysis, potentially modifying risk behaviour, and increasing uptake of HCV screening and
19
20 antiviral treatment in this population.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Article Summary****Article focus:**

- Although the risk factors for incident infection are well established, the literature suggests that a number of barriers may prevent PWID presenting for screening.
- Study developed a scoring tool based on demographic and injecting risk behaviors to identify those who require additional, non-routine serological screening for HCV by assessing their personal risk.

Key Messages:

- Current clinical practice guidelines recommend HCV screening of individuals with a history of injecting drugs.
- However, this recommendation focuses on a single risk factor (i.e. injecting drug use) whereas considering the cumulative effect of multiple risk factors among PWID can more precisely identify people in need of additional, non-routine screening.

Strengths and limitations:

- Our prediction equation is based on 11 years of data and more than 16,000 participants. Ideal risk assessment methods or prediction models should be derived from large representative samples.
- The study population is limited to those who participated in the ANSPS, which may result in selection bias.
- We were not able to differentiate between acute, recent and chronic infections.

1
2
3
4
5
6
7
8
9
10
11 **Competing interest:** None.

12
13 **Ethics approval:** Ethical approvals for the survey were obtained from Institutional Ethics Committees
14 associated with the investigators and participating NSP sites.
15
16

17
18
19
20 **Contributors:** HW implemented the study, analysed the data and wrote the first draft. LM, JI, LT and
21 DW helped drafting, interpreting the data and finalizing the manuscript. All authors saw and approved
22 the final, submitted version of the manuscript.
23
24

25
26
27 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of
28 all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to
29 the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in
30 BMJ editions and any other BMJ PGL products and sublicences to exploit all subsidiary rights, as set
31 out in our licence (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>)."
32 should be made in the manuscript.
33
34
35
36
37
38
39
40
41
42
43

44 **Provenance and peer review:** Not commissioned; externally peer reviewed.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- [1] McGinn T, O'Connor-Moore N, Alfandre D, Wisnivesky J. Validation of a Hepatitis C Screening Tool in Primary Care. *Arch Intern Med* **2008**; 168(18):2009-13.
- [2] Thorpe LE, Ouellet LJ, Hershov R et al. Risk of Hepatitis C Virus infection among Young Adult Injecting Drug Users Who Share Injecting Equipment. *American Journal of Epidemiology* **2002**; 155:7:645-653.
- [3] Alter MJ, Kruszon-Moran D et al. The prevalence of hepatitis C virus infection in the United States, 1998 through 1994. *New England Medical Journal* **1999**; 341:556-62.
- [4] Villano S. A., Vlahov D., Nelson K. E., Lyles C. M., Cohn S. & Thomas D. L. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. *J Clin Microbiol* 1997; **35**: 3274–7;
- [5] Garfein RS, Doherty MC, Monterroso ER, et al. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. *J Acq Immune Defic Synd Hum Retrovirol* **1998**; 18:11–19.
- [6] Hahn JA, Page-Shafer K, Lum PJ et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. *J Infect Dis* **2002**; 186:1558–64.
- [7] Hagan H, Thiede H, Des Jarlais DC. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. *Epidemiology* **2004**; 15: 543–9.
- [8] Hagan H, Thiede H, Weiss NS et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. *Am J Public Health* **2001**; 91: 42–6.

- 1
2
3 [9] Falster K, Kaldor J and Maher L. Hepatitis C Virus acquisition among Injecting Drug Users: a cohort
4
5 analysis of a national repeated cross-sectional survey of needle and syringe program attendees in
6
7 Australia, 1995-2004. *Journal of Urban Health* **2008** [doi:10.1007/s11524-008-9330-7].
8
9
10
11 [10] Hahn JA, Page-Shafer K, Lum PJ et al. Hepatitis C virus seroconversion among young injection
12
13 drug users: relationships and risks. *J Infect Dis* **2002**; 186: 1558–64.
14
15
16
17 [11] Maher L, Jalaludin B, Chant KG et al. Incidence and risk factors for hepatitis C seroconversion in
18
19 injecting drug users in Australia. *Addiction* **2006**; 101(10): 1499-1508.
20
21
22
23 [12] Maher L, Li J, Jalaludin B et al. High hepatitis C incidence in new injecting drug users: a policy
24
25 failure? *Aust N Z J Public Health* **2007**; 31(1): 30-35.
26
27
28
29 [13] Patrick DM, Tyndall MW, Cornelisse PG et al. Incidence of hepatitis C virus infection among drug
30
31 users during an outbreak of HIV infection. *Can Med Assoc J* **2001**; 165: 889–95.
32
33
34
35 [14] Miller CL, Johnston C, Spittal PM et al. Opportunities for prevention: hepatitis C prevalence and
36
37 incidence in a cohort of young injection drug users. *Hepatology* **2002**; 36: 737–42.
38
39
40
41 [15] Davis M, Rhodes T. Beyond prevention? *International Journal of Drug Policy* **2004**; 15:123-31.
42
43
44 [16] National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually
45
46 transmissible infections in Australia. Annual Surveillance Report 2009. National Centre in HIV
47
48 Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW.
49
50
51
52 [17] NCHECR. Hepatitis C Virus Projections Working Group, Sydney: NCHECR, **2006**.
53
54
55 [18] Kwiatkowski CF, Fortiun Corsi K, Booth RE. The association between knowledge of hepatitis C
56
57 virus status and risk behaviors in injection drug user. *Addiction* **2002**; 97:1289-94.
58
59
60

- 1
2
3 [19] Gerlach J, Diepolder H, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and
4
5 treatment-induced viral clearance. *Gastroenterology* **2003**; 125:80-8;
6
7
8
9 [20] Kamal SM, Fouly AE, Kamel RR et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of
10
11 onset of therapy on sustained virologic response. *Gastroenterology* **2006**; 130:632-638;
12
13
14 [21] Gregory JD, Hellard M, Matthews GV, et al. Effective Treatment of Injecting Drug Users with
15
16 recently acquired hepatitis C virus infection. *Gastroenterology* **2010**; 138:123-135;
17
18
19
20 [22] Topp L, Iversen, J, Wand H, Day C, Kaldor J, Maher L. Representativeness of injecting drug users
21
22 who participate in HIV surveillance: results from Australia's Needle and Syringe Program Survey. *J*
23
24 *Acquir Immune Defic Syndr* **2008**; 47(5), 632-638.
25
26
27
28 [23] MacDonald M, Crofts N, Kaldor J Transmission of hepatitis C virus: rates, routes, and cofactors.
29
30 *Epidemiol Rev* **1996**; 18(2), 137-148.
31
32
33
34 [24] MacDonald M, Wodak AD, Ali R et al. HIV prevalence and risk behavior in needle exchange
35
36 attenders: a national study. *The Collaboration of Australian Needle Exchanges. Med J Aust* **1997**;
37
38 166(5),237-240.
39
40
41
42 [25] MacDonald MA, Wodak AD, Dolan KA et al. Hepatitis C virus antibody prevalence among injecting
43
44 drug users at selected needle and syringe programs in Australia, 1995-1997. *Collaboration of*
45
46 *Australian NSPs. Med J Aust* **2000**; 172(2),57-61.
47
48
49
50 [26] Schmidt MI, Duncan BB, Bang H et al. Identifying individuals at high risk for diabetes: the
51
52 *Atherosclerosis Risk in Communities study. Diabetes Care* **2005**; 28:2013-2018.
53
54
55
56
57
58
59
60

1
2
3 [27] Gonen M. Analyzing Receiver Operating Characteristic Curves with SAS **2007**. Cary, NC: SAS
4
5 Institute;

6
7 [28] Sackett D, Straus SE, Richardson WS et al. Evidence- Based Medicine: How to Practice and Teach
8
9 EBM. 2nd ed. Philadelphia: Churchill Livingstone; **2000**.

10
11 [29] Wand H, Spiegelman D, Law M et al. Estimating population attributable risk for hepatitis C
12
13 seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
14
15 Addiction **2009**, 104(12), 2049-2056(8).
16
17

18
19 [30] Maher L, Iversen J, Kaldor J. Measuring effectiveness of needle and syringe exchange programs
20
21 for prevention of HIV among injecting drug users: Response to Amundsen. Addiction **2006**;
22
23 101(12):1834-6.
24
25

26
27 [31] Volk M, Tocco R, Saini S, Lok A. Public health impact of antiviral therapy for hepatitis C in the
28
29 United States. Hepatology **2009**;50:1-6
30
31

32
33 [32] Edlin BR, Kresina TF, Raymond DB et al. Overcoming Barriers to Prevention, Care, and Treatment
34
35 of Hepatitis C in Illicit Drug Users. CID **2005**; 40 (Suppl 5): S276-S285.
36
37

38
39 [33] White B, Day C, Maher L. Self reported risk behavior among injecting drug users: Self versus
40
41 assisted questionnaire completion. AIDS Care **2007**; 19(3): 441-447.
42
43

44
45 [34] Vickers AJ, Basch E, Kattan MW. Against diagnosis. Ann Intern Med. **2008**; 149:200-3. [PMID:
46
47 18678847]
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Risk factors for Hepatitis C Virus (HCV)

Characteristics	HCV Seronegative N= 5,214 (49%)	HCV Seropositive N= 5,448 (51%)
Mean age at survey (\pm SD)	29 \pm 8	34 \pm 9
<25 years, %	35	16
25-29 years, %	24	19
30-39 years, %	29	37
40+ years, %	12	28
Female, %	33	35
Indigenous, %	8	10
Mean age at first injection (\pm SD)	20 \pm 6	19 \pm 6
Mean years of injecting (\pm SD)	9 \pm 7	15 \pm 9
<5 years, %	26	12
5-9 years, %	28	21
10-16 years, %	23	28
17+ years, %	14	40
Ever been in Prison, %	17	33
Been in prison last year, %	11	22
Drug injecting behaviors (last month)		
Drug injected, %		
Amphetamine/methamphetamine	51	28
Heroin	35	48
Cocaine	3	5
Methadone	4	8
Morphine	7	9
Buprenorphine	1	2
Others ¹	9	8
Injecting daily or more, %	50	58
Receptive sharing needle/syringe, %	15	18
Receptive sharing ancillary equipments ² , %	33	38
Injected by another, %	14	12
New needle syringe in every injection	72	68
Injected in Public	46	52

¹benzos, anabolic steroids, mixed drugs, other drugs or not reported

²water, spoon, filter, tourniquet

Table 2: Multivariable logistic regression: Odds Ratios (OR) and 95% confidence intervals (CI) for HCV infection scoring by age groups

	<25 N=2,686			25-29 N=2,291			30-39 N=3,563			40+ N=2,122		
	OR (P)	β*10	Score	OR (P)	β*10	Score	OR (P)	β*10	Score	OR (P)	β*10	Score
Sex												
Male	1	-	0	1			1			-		
Female	1.4	3.4	3	1.5 (<0.001)	4.1	4	1.4 (0.002)	3.3	3			
Indigenous												
No	-	-	-	-			1	-	-			
Yes							1.3 (0.04)	2.8	3			
Ever been in Prison?												
No	1	1	0	1			1			1		
Yes	2.2 (<0.001)	7.8	8	2.8 (<0.001)	10.2	10	1.9 (<0.001)	6.4	6	1.4 (0.003)	3.4	3
Years of injecting												
<5 year	1	-	0	1						1		
5-9 years	2.0 (<0.001)	6.8	7	1.7 (<0.001)	5.5	6	1.9 (<0.001)	6.5	7	1.5 (0.149)	3.7	4
10+ years	3.1 (<0.001)	11.1	11	2.4 (<0.001)	8.9	9	3.6 (<0.001)	12.7	13	4.6 (<0.001)	15.3	15
Drug last injected												
Amphetamine/methamphetamine	1	-	0	1			1	-		1		
Morphine	2.3 (<0.001)	8.3	8	1.7 (0.009)	5.5	6	1.9 (<0.001)	6.7	7	1.9 (<0.001)	6.7	7
Others ²	2.0 (<0.001)	6.7	7	1.6 (0.010)	4.7	5	1.8 (<0.001)	5.9	6	1.5 (0.053)	4.0	4
Heroin	3.0 (<0.001)	11.1	11	2.7 (<0.001)	10.0	10	3.0 (<0.001)	10.7	11	2.5 (<0.001)	9.0	9
Cocaine	6.4 (<0.001)	18.6	19	3.6 (<0.001)	12.7	13	3.0 (<0.001)	10.9	11	3.6 (<0.001)	12.8	13
Methadone	3.3 (<0.001)	11.3	11	3.4 (<0.001)	12.2	12	3.0 (<0.001)	11.0	11	3.1 (<0.001)	11.3	11
Buprenorphine	3.2 (0.003)	11.4	11	2.8 (0.004)	10.4	10	2.8 (0.001)	10.2	10	1.9 (0.141)	6.2	6
(Drug injecting behaviors last month)												
Injecting frequency												
Less than daily	1	-	0	1								
Daily or more	1.4 (0.001)	3.1	3	1.5 (<0.001)	4.0	4	-	-	-	-	-	
Receptive sharing needle/syringe												
No	-			1			1	-		-		
Yes	-			1.4 (0.005)	3.4	3	1.4 (0.002)	3.3	3			
Receptive sharing ancillary equipment²												
No	1	1	0	1						1		
Yes	1.3 (0.006)	2.5	3	1.3 (0.003)	3.0	3	-	-	-	1.5 (0.001)	3.8	4

¹benzos, anabolic steroids, mixed drugs, other drugs or not reported

²water, spoon, filter, tourniquet

Table 3: Odds Ratios (OR) and 95% confidence intervals (CI) & for HCV infection by quintiles of HCV scoring

	Age <25 years		Age 25-29 years		Age 30-39 years		Age 40 plus	
Development Data Set	OR (95% CI)	P ⁰	OR (95% CI)	P ⁰	OR (95% CI)	P ⁰	OR (95% CI)	P ⁰
HCV Risk score¹		<0.001		<0.001		<0.001		<0.001
Fifth 1	1		1		1		1	
Fifth 2	1.90 (1.33,2.69)		2.60 (1.88,3.57)		2.23 (1.72,2.89)		2.63 (1.94,3.58)	
Fifth 3	2.77 (1.92,4.01)		4.12 (3.00, 5.65)		4.07 (3.13,5.28)		4.56 (3.10,6.70)	
Fifth 4	5.40 (3.95,7.38)		4.85 (3.53,6.66)		5.40 (4.16,7.02)		5.86 (4.25,8.08)	
Fifth 5	10.31 (7.44,14.29)		12.40 (9.08,16.91)		9.10 (7.04,11.75)		7.78 (5.61,10.80)	
Population attributable risk for HCV score (%)² (95% CI)								
lowest v upper four fifth	78% (75%, 81%)		82% (80%, 84%)		80% (78%, 82%)		80% (77%, 82%)	
lower two v upper three fifth	74% (72%, 77%)		76% (74%, 78%)		74% (73%, 77%)		72% (69%, 74%)	
Validation Data Set								
HCV Risk score¹		<0.001		<0.001		<0.001		<0.001
Fifth 1	1		1		1		1	
Fifth 2	1.92 (1.12,3.28)		2.75 (1.73,4.38)		2.73 (1.94,3.85)		1.98 (1.30,3.02)	
Fifth 3	4.70 (2.75,8.04)		4.33 (2.78,6.77)		5.34 (3.74,7.63)		5.03 (2.78,9.10)	
Fifth 4	6.00 (3.76,9.56)		6.13 (3.93,9.56)		7.46 (5.19,10.74)		3.79 (2.44,5.87)	
Fifth 5	11.97 (7.41,19.32)		9.28 (6.07,14.19)		10.68 (7.56,15.10)		5.42 (3.50,8.42)	
Population attributable risk for HCV score (%)² (95% CI)								
lowest v upper four fifth	82% (79%, 85%)		80% (77%, 83%)		84% (82%, 85%)		73% (68%, 77%)	
lower two v upper three fifth	79% (76%, 81%)		74% (71%, 77%)		78% (76%, 79%)		67% (62%, 71%)	

⁰ Test for trend

¹ HCV score for age <25 was <7 for fifth 1, 7-<14 for fifth 2, 14-<17 for fifth 3, 17-<24 for fifth 4 and 24+ for fifth 5; for age 25-29 was <12 for fifth 1, 12-<17 for fifth 2, 17-<22 for fifth 3, 22-<26 for fifth 4 and 24+ for fifth 5; for age 30-39 was <13 for fifth 1, 13-<19 for fifth 2, 19-<24 for fifth 3, 24-<27 for fifth 4 and 27+ for fifth 5; for age 40 plus was <15 for fifth 1, 15-<22 for fifth 2, 22-<24 for fifth 3, 24-<27 for fifth 4 and 27+ for fifth 5;

Table 4: Optimal characteristics of HCV Scoring¹

	Age <25 years		Age 25-29 years		Age 30-39 years		Age 40 plus	
Score cut points ²	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity
Development Data Set (n=10,662)								
≥ 10	96%	17%	99%	9%	99%	7%	98%	10%
≥ 15	92%	32%	95%	23%	97%	15%	97%	19%
≥ 20	74%	60%	86%	42%	90%	36%	94%	24%
≥ 25	55%	74%	68%	64%	73%	57%	75%	54%
Validation Data Set (n= 5,465)								
≥ 10	96%	18%	99%	8%	99%	10%	99%	10%
≥ 15	94%	32%	95%	25%	97%	19%	97%	15%
≥ 20	76%	57%	88%	40%	87%	43%	94%	21%
≥ 25	59%	72%	67%	61%	73%	61%	74%	52%

¹HCV Score :

For age < 25: (female)*3+ (indigenous) *0 + (Injecting 5-9 years)*7 + (Injecting 10+ years) *11+ Morphine*8 + (other drugs e.g. benzos, anabolic steroids, mixed drugs, other drugs)*7 + (heroin)*11 + (cocaine)*19 + (methadone)*11 + (morphine)*8 + (Buprenorphine) *11 + (daily or more)*3 + (shared needle and syringe)*0 + (shared other equipment)*3 + (been in prison)*8

For age 25 -29 year: (female)*4+ (indigenous) *0 + (Injecting 5-9 years)*6 + (Injecting 10+ years) *9+ Morphine*6 + (other drugs e.g. benzos, anabolic steroids, mixed drugs, other drugs)*5 + (heroin)*10 + (cocaine)*13 + (methadone)*12 + (morphine)*5 + (Buprenorphine) *10 + (daily or more)*4 + (shared needle and syringe)*4 + (shared other equipment)*0 + (been in prison)*6

For age 30 -39 year: (female)*3+ (indigenous) *3 + (Injecting 5-9 years)*7 + (Injecting 10+ years) *13+ Morphine*7 + (other drugs e.g. benzos, anabolic steroids, mixed drugs, other drugs)*6 + (heroin)*11 + (cocaine)*11 + (methadone)*11 + (morphine)*7+ (Buprenorphine) *10 + (daily or more)*0 + (shared needle and syringe)*3 + (shared other equipment)*0 + (been in prison)*6

For age 40 + year: (female)*0+ (indigenous) *0 + (Injecting 5-9 years)*4 + (Injecting 10+ years) *15 + Morphine*7 + (other drugs e.g. benzos, anabolic steroids, mixed drugs, other drugs)*4 + (heroin)*9 + (cocaine)*13 + (methadone)*11 + (morphine)*7+ (Buprenorphine) *6 + (daily or more)*0 + (shared needle and syringe)*3 + (shared other equipment)*0 + (been in prison)*6

²Approximate cut points for the first, second, third and the fourth quintiles.



Developing and validating a scoring tool for identifying people who inject drugs at increased risk of hepatitis C virus infection

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000387.R2
Article Type:	Research
Date Submitted by the Author:	26-Oct-2011
Complete List of Authors:	Wand, Handan; University of New South wales Iversen, Jenny; The Kirby Institute Wilson, David; The Kirby Institute Topp, Libby; The Kirby Institute Maher, Lisa; The Kirby Institute
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Infectious diseases
Keywords:	INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES, Infection control < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts

1
2
3
4
5 **Developing and validating a scoring tool for identifying people who inject drugs at**
6 **increased risk of hepatitis C virus infection**
7
8
9

10
11
12
13
14 Handan Wand, Jenny Iversen, David Wilson, Libby Topp and Lisa Maher

15
16
17 The Kirby Institute, Sydney, Australia, University of New South Wales

18
19
20
21 October 26, 2011

22
23
24 Revised

25
26
27 **Corresponding author:**

28
29
30 Handan Wand, PhD

31
32
33 The Kirby Institute, University of New South Wales, Sydney, Australia

34 Telephone: +61-2-9385 0900

35 Facsimile: +61-2-9385 0920

36 Email: hwand@nchecr.unsw.edu.au

37
38
39
40
41
42
43 Word counts:

44
45 Abstract: 261

46
47 Manuscript: 3016
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Objectives: To develop and validate a scoring tool based on demographic and injecting risk behaviors to
4 identify those who require additional, non-routine serological screening for hepatitis C virus (HCV) by assessing
5 their personal risk.
6
7

8
9
10
11 Design: Cross sectional and prospective cohorts.
12

13
14
15
16 Setting: People who inject drugs (PWID) and attended Needle and Syringe Programs (NSP) in Australia during
17 the period of 1998-2008.
18
19

20
21
22
23 Participants: Cross sectional data included 16,127 PWID who attended NSP in Australia. Prospective data
24 included 215 HCV negative PWID who were recruited through street-based outreach, methadone clinics in
25 Australia.
26
27

28
29
30
31 Primary and secondary outcome measures: HCV seroprevalence in the cross sectional and HCV
32 seroconversions in the prospective datasets.
33
34

35
36
37
38 Results: Current study included 16,127 PWID who attended NSP in Australia. Type of drug last injected,
39 frequency and duration of injecting, sharing needles and syringes or other injecting equipment and imprisonment
40 history were associated with HCV infection in all age groups. Strong relationships between an individual's 'HCV
41 score' and their risk of testing HCV antibody positive were observed. An estimated 78% (95% CI: 75%, 81%),
42 82% (95% CI: 80%, 84%), 80% (95% CI: 78%, 82%) and 80% (95% CI: 77%, 82%) of HCV infections across the
43 age groups (<25, 25-29, 30-39 and 40 or older) would be avoided if participants in the upper four quintiles of
44 HCV scores fell instead into the lowest quintile.
45
46
47
48
49
50

51
52 Conclusions: Knowledge of HCV status has important implications for public health and care and treatment. Risk
53 assessment strategies may assist in alerting PWID who are at increased risk of HCV infection to present for
54 testing.
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Key words: Hepatitis C infection, injecting drug users, risk assessment

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2011-000387 on 4 January 2012. Downloaded from <http://bmjopen.bmj.com/> on August 17, 2023 by guest. Protected by copyright.

INTRODUCTION

Worldwide, infection with hepatitis C virus (HCV) is common among people who inject drugs (PWID) [1]. Estimates suggest that more than 70% of new cases of HCV infection are associated with injecting drug use [2,3]. Epidemiologic studies have identified independent risk factors for HCV infection, including sharing of contaminated needles and syringes [4-7] and other injecting equipment [8, 9], female gender [10,11], duration of injecting [12] and intravenous cocaine use [13, 14]. Although the risk factors for incident infection are well established, the literature suggests that a number of barriers may prevent PWID presenting for screening and many PWID face the possibility of HCV infection with a sense of inevitability, fostered by structural barriers to risk avoidance [15]. PWID are a priority population in Australia as HCV prevalence remains high in this group. The burden of advanced liver disease (liver failure and hepatocellular carcinoma) continues to grow among HCV-infected people [16]. It is estimated that 5,300 Australians are living with HCV-related cirrhosis and this figure is expected to double by 2020 without increased therapeutic intervention [17]. Despite the mounting burden of disease and recent advances in antiviral treatments, HCV treatment uptake among PWID remains very low (1-2% of chronic hepatitis C cases) [17]. A major public health challenge is to more effectively identify individuals with HCV before the development of significant clinical consequences.

Our study aimed to develop a scoring tool that can be used by PWID and primary care providers to identify individuals at increased risk of HCV infection. With increasing recognition of the clinical benefits of early diagnosis and treatment uptake [18-20], a simple self-administered tool may provide a means for PWID to identify personal risk and to modify risk behavior and/or seek health care/further assessment.

1
2
3 A large database of serial cross sectional samples of PWID attending Needle and Syringe Programs
4
5 (NSP) in Australia (1998-2008) was used to develop a statistical model underpinning the tool. **Cross-**
6
7 **sectional (internal) and prospective (external) validation studies were carried** out on the HCV risk
8
9 assessment algorithm.

10
11
12 The following characteristics were considered essential in the development of the new prediction
13
14 algorithm: (1) the use of routinely available and minimally intrusive variables and (2) estimation of the
15
16 cumulative effect of concurrent risk factors on the likelihood of HCV prevalence. We are unaware of
17
18 any studies to date that have quantified the cumulative effect of concurrent risk factors on the
19
20 acquisition of HCV infection among PWID.
21
22
23
24

25 26 27 28 **STUDY POPULATION**

29
30 The Australian Needle and Syringe Program Survey (ANSPS) is a serial cross-sectional study conducted
31
32 annually over a one to two week period since 1995. More than 50 NSP sites participate annually, with
33
34 sites selected on the basis of geographic coverage, willingness to participate and an ability to recruit a
35
36 minimum of 20 survey respondents. The survey methods have been described in detail elsewhere [21-
37
38 24]. In brief, all PWID who attended participating ANSPS sites during the designated survey period
39
40 were invited to participate. Participation was anonymous and voluntary and there was no financial
41
42 reimbursement. Following provision of verbal informed consent to participate, respondents were
43
44 asked to complete a brief, self-administered questionnaire on demographic characteristics and
45
46 injecting and sexual risk behaviors (www.web.med.unsw.edu.au/nchecr), and to provide a capillary
47
48 blood sample for antibody HIV and HCV testing. The current study used data for the period 1998-
49
50 2008, involving more than 16,000 individuals. Response rates ranged from 38%-50% during the study
51
52
53
54
55
56
57
58
59
60

1
2
3 period. Previous research has demonstrated the representativeness of ANSPS samples of the broader
4
5 population of NSP clients [21].
6
7

8
9 Capillary blood was obtained by finger prick using single-use, disposable lancets and cotton-fiber
10
11 blotting paper. Specimens were kept at room temperature at the survey sites, then couriered to a
12
13 central collection point before they were forwarded to the laboratory. A modified, third generation
14
15 enzyme immunoassay (Abbott hepatitis C 3.0, Chicago, IL, USA) was used to test for HCV antibody. A
16
17 modified cutoff value for optical density was calculated to capture greater than 95% of the
18
19 seronegative population. Specimens were considered positive for HCV antibody if the optical density
20
21 to cutoff ratio was greater than or equal to one on initial and subsequent testing.
22
23
24
25

26
27 Ethical approval was obtained from the Human Research Ethics Committee (HREC) at the University
28
29 of New South Wales, as well as from relevant jurisdictional and site specific HRECs.
30
31
32

33 34 **STATISTICAL ANALYSES**

35
36 A split-sample method was used to develop and subsequently validate a risk equation and scoring
37
38 system. Participants were randomly allocated to either the development (n=10,662; 67%) or internal
39
40 validation (n=5,331; 33%) sample datasets.
41
42
43

44
45 We selected a range of demographic and injecting behavior variables as potential determinants of
46
47 HCV infection. These included gender, Indigenous status, imprisonment history, country of birth,
48
49 language spoken at home, drug last injected, frequency and duration of injecting, sharing of needles
50
51 and syringes and other injecting equipment (e.g. water, filter, spoon, tourniquet), public injecting,
52
53 and drug treatment history. All analyses were stratified by age groups (<25, 25-29, 30-39 and 40+).
54
55
56
57
58
59
60

1
2 We used descriptive statistics to characterize the groups according to antibody HCV serostatus: mean
3 and standard deviation (SD) for continuous variables and percentages for categorical variables.
4
5
6
7
8 Logistic regression was used to create a predictive model based on the development data set. We
9
10 used all non-missing observations available in the relevant analyses as only a small proportion of
11
12 observations had any missing data (except for the variable “imprisonment history”). Cox regression
13
14 analysis was used to validate the scoring tool for HCV seroconversion in external validation set. All
15
16 analyses were conducted using SAS statistical software version 9.2 (SAS Institute Inc. Cary, North
17
18 Carolina) and STATA 10.0 (College Station, Texas).
19
20
21
22

23 **Derivation of a screening score:**

24
25
26 Using the development data set (n=10,662), we included a comprehensive list of predictors known to
27
28 be associated with HCV antibody seropositivity in an initial model. Specifically, we included the main
29
30 effects of all variables listed in Table 1 and their interaction effects. We first analyzed the univariate
31
32 associations between the independent variables and HCV seropositivity. Backward elimination was
33
34 used to reach the final multivariate model, in which factors with the largest *P* value were sequentially
35
36 deleted until only significant predictors remained. We then created a weighted scoring system by
37
38 rounding all regression coefficients up to the nearest integer (that is, the smallest integer greater than
39
40 the estimate). This method was based on the β -coefficients (or log of the odds ratios) rather than
41
42 odds ratios, which can be excessively influenced by only a few factors [25-27]. Once the final model
43
44 was defined, we created integer weights for each variable. We calculated these weights by
45
46 multiplying the model coefficients by 10. Using the rounded weights in the risk function, we
47
48 estimated the participant-specific probabilities of HCV seropositivity and characterized the degrees of
49
50 risk based on cut-off points of the probability distribution.
51
52
53
54
55
56
57
58
59
60

Cross-sectional internal validation:

We examined the predictive validity of the scoring system using the internal validation datasets (n=5,331). We also assessed the predictive validity of this scoring system on the subsequent risk of HCV antibody seroconversion using prospective data collected from individuals who visited ANSPS sites multiple times and tested HCV seronegative at their first visit.

We used the cross-sectional dataset to check the sensitivity and robustness of the new screening score. We computed standard validation measures: the proportion of antibody HCV seropositive specimens, sensitivity, specificity, positive likelihood and negative likelihood ratio and the area under the receiver operating characteristic curve (AUC) as discrimination statistics. We also assessed the diagnostic characteristics of different cut-points based on the total score in the development as well as validation datasets. The purpose of this analysis was to assess whether the combination of risk factors under consideration could predict those at increased risk with acceptable accuracy.

Prospective external validation:

We have also conducted a prospective external validation study to assess the performance of the scoring system for HCV seroconversion among the new PWID. The details of the study population have been described elsewhere [12]. In brief, as part of a multi-site study between 1999 and 2002, 215 hepatitis C seronegative PWID were recruited through street-based outreach, methadone clinics in South Western Sydney and followed-up at 3–6- monthly intervals. Using the Cox regression coefficients in the risk function, the participant-specific probability of HIV seroconversion was estimated. A rule to characterize different degrees of risk based on cut-off points of the probability distribution was then established. We also assessed the diagnostic features and characterized different degrees of risk based on cut-off points of the probability distribution.

Population attributable risk:

After we calculated and validated the HCV screening score, we estimated population attributable risks, which estimates the percentage of HCV infections that would not have occurred if all participants had been assigned the “lowest risk” (first quintile) category of the HCV screening score. We calculated population attributable risks using a previously described method [28] that was applied to this study design and appropriate for use with multivariable adjusted relative risks.

RESULTS

Our study population comprised 10,662 individuals in the development dataset. Table 1 summarizes participant characteristics by HCV antibody serostatus. The overall prevalence of HCV was 51%. HCV seropositive participants tended to be older and more likely to report a longer duration of injecting, heroin as the drug last injected, a history of imprisonment, daily or more frequent injecting, public injecting and sharing needles and syringes and other injecting equipment.

Table 2 presents the final multivariate logistic regression model derived from the development data set by age groups. History of imprisonment, duration of injecting (5-9, 10+ years), drug last injected (heroin, cocaine, methadone, morphine, buprenorphine and others), needle and syringe sharing and sharing of ancillary equipment were all significantly associated with increased risk of antibody HCV seropositivity across all age groups. Injecting frequency (daily or more) was determined to be a significant risk factor for those aged less than 30 years. Female gender was associated with an increased risk of HCV seroprevalence for those younger than 40 years of age. Indigenous status was a significant predictor for HCV infection among people aged 30-39 years. Drug last injected and

1
2
3 duration of injecting each required multiple categories to capture the risk gradient, whereas other risk
4
5 factors were binary. The risk factors collectively yielded an AUC of 0.73 (95% CI: 0.70, 0.76), 0.72 (95%
6
7 CI: 0.70, 0.75), 0.73 (95% CI: 0.70, 0.76) and 0.66 (95% CI: 0.64, 0.71) for the age groups <25, 25-29,
8
9 30-39 and 40 plus (data not shown). There were no significant interactions between injecting risk
10
11 behaviors and gender across age groups (data not shown).
12
13

14
15
16 Table 3 shows the odds ratios (ORs) from the logistic regression models and population attributable
17
18 risks of HCV infection for the quintiles of the risk scores by age groups for the development and
19
20 validation datasets. There was a linear trend towards increasing HCV infection with increasing score
21
22 regardless of the age groups in both datasets (trend, p-value<0.001). Using the development dataset,
23
24 we estimated population attributable risks (95% CI) for the upper four quintiles of the scores. Results
25
26 showed that 78% (75%, 81%), 82% (80%, 84%) and 80% (77%, 82%) of HCV infections across the age
27
28 groups would be avoided if participants in the upper four quintiles of the HCV scores instead fell into
29
30 the lowest quintile. Results from the validation dataset were consistent with those from the
31
32 development dataset (Table 3). We also assessed the diagnostic characteristics of cut-points
33
34 (according to first, second, third and the fourth quintiles in overall population) for total score in the
35
36 development as well as the validation datasets (Table 4). An increased risk of HCV was clearly
37
38 associated with increasing scores. For example, a cut-point score of 10 or higher distinguished a
39
40 'increased risk' group with a sensitivity of 96% or higher; similarly a cut-point 20 or higher yielded at
41
42 least 92% sensitivity in all age groups in the development dataset; in cross sectional validation,
43
44 sensitivity was estimated to be at least 94% across the age groups for the cut-point 10/15 or more
45
46 and at least 76% for 20 or more. Figure 1 illustrates the risk of PWID being HCV seropositive as a
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 continuous function of the total score. Across all age groups, increasing scores were clearly associated
4
5 with increased risk of HCV antibody positivity.
6
7
8
9

10
11 A total of 61 HCV seroconversions were observed during follow-up with an overall incidence rate of
12
13 45.8 per 100 person-years (95% CI: 35.6, 58.8) in our external prospective validation dataset. Results
14
15 from our prediction model were consistent with the previous results and had the acceptable validity
16
17 (Table 5). Higher number of risk factors associated with increased risk of HCV seropositivity compared
18
19 two or less risk factors (reference) (Hazard ratio (HR):1.10, 95% CI: 0.74,1.60, HR:1.15,95%
20
21 CI:0.78,1.65, HR:2.17, 95% CI: 1.45,3.17 and HR:3.19, 95% CI: 2.30, 5.51 for 3, 4, 5 and 6 or more risk
22
23 factors respectively). Overall sensitivity of the scoring tool was 73% sensitivity and 33% specificity
24
25 (Figure 2);
26
27
28
29
30
31
32
33

34 DISCUSSION

35
36 In this study, we developed a scoring tool based on data from ~16,000 PWID who attended ANSPS
37
38 sites between 1998 and 2008. The tool was validated to more accurately identify those at increased
39
40 risk of HCV infection. Current Australian guidelines recommend HCV antibody screening in all
41
42 individuals with risk factors for infection regardless of patient characteristics and settings [29].
43
44 Increasing the rate of HCV diagnosis and, in particular, diagnosis of acute infection and providing
45
46 access to effective antiviral treatment has the potential to improve individual quality of life and
47
48 reduce the burden of HCV infection. Being unaware of one's HCV serostatus has been identified as a
49
50 major barrier to increasing HCV treatment uptake, including among PWID [30-31]. While a relatively
51
52 high proportion (64%) of participants in the ANSPS reported recent HCV testing, HCV antibody
53
54
55
56
57
58
59
60

1
2
3 negative respondents were less likely to do so than antibody positive respondents (60% versus 67%).
4
5 One in five (20%) HCV antibody negative participants had not been tested for HCV in the last twelve
6
7 months, and a further 20% had never been tested (www.web.med.unsw.edu.au/ncheccr/Publications).
8
9
10 This suggests that both uptake and frequency of testing could be improved.
11

12
13 **Although our scoring tool was developed for the prediction of current HCV diagnoses and not incident**
14 **HCV in the future, strong consistency in risk factors for the prediction incident events of HCV was**
15 **shown in prospective validation of the tool. Therefore, we expect that the same set of risk factors in**
16 **our model plays an important role in the prediction of future HCV seroconversion.**
17
18
19
20
21
22
23
24
25

26 The intention of this study was not to identify a unique and specific cut-point of risk above which to
27
28 target screening, but rather, to assess whether risk factors under consideration could predict those at
29
30 increased risk accurately in order to consider the tool's use in facilitating increased screening. With a
31
32 high background HCV prevalence of ~70% among Australian PWID, all PWID should be screened for
33
34 HCV. However, identification of just one of our listed risk factors substantially increased the likelihood
35
36 of infection. Although Australia has screening guidelines for hepatitis C, current guidelines do not
37
38 target specific attributes or injecting risk behaviours [29]. By focusing on particular characteristics
39
40 and specific high-risk behaviors, tools such as the one developed in this study may allow for more
41
42 targeted identification of individuals at increased risk of infection. If used as a self-administered
43
44 questionnaire, it is likely that respondents will answer more accurately [32]. Since the vast majority
45
46 of new HCV diagnoses in Australia are among people with a history of injecting drug use [21], this tool
47
48 provides a valuable resource which could inform the establishment of more focused national
49
50 screening guidelines.
51
52
53
54
55
56
57
58
59
60

1
2
3 Further, although current clinical practice guidelines recommend HCV screening of individuals with a
4
5 history of injecting drugs, this recommendation focuses on a single risk factor (i.e. injecting drug use)
6
7 whereas considering the cumulative effect of multiple risk factors can more precisely identify people
8
9 in need of additional, non-routine screening. This is particularly pertinent in resource-constrained
10
11 environments (including time-restricted clinical settings). Our methodology made use of a range of
12
13 coexisting risk factors that were identified by a rigorous statistical approach in order to accurately
14
15 identify the most relevant factors for HCV infection.
16
17
18
19

20
21 Risk calculation approaches have been extensively used in decision making about public health and
22
23 clinical care and have even been proposed as an alternative to diagnosis for some diseases [33]. Our
24
25 risk calculation was based on a statistical method that yielded a systematic scoring system for
26
27 carefully selected predictors, guided not only by numerical and scientific evidence but also feasibility
28
29 perspectives. We chose categorized variables which highlighted the important risk factors to
30
31 motivate high-risk persons to be screened or to modify behaviors. This combination of factors may
32
33 explain the enhanced properties of our scoring tool.
34
35
36
37
38

39
40 Our study has several strengths, including being the first to validate a predictive model through
41
42 internal cross sectional and prospective data sets. Our prediction equation is based on 11 years of
43
44 data and more than 16,000 participants. Ideal risk assessment methods or prediction models should
45
46 be derived from large representative samples. The current study has several limitations. First, the
47
48 study population is limited to those who participated in the ANSPS, which may result in selection bias.
49
50 However, the ANSPS has been shown to be broadly representative of PWID attending NSPs [21].
51
52
53
54
55 Second, we were not able to differentiate between acute, recent and chronic infections.
56
57
58
59
60

1
2
3 Risk factor screening and identification allows for patients to be educated regarding the risks of
4
5 injection drug use and needle sharing. Appropriate testing and diagnosis of HCV allows for the patient
6
7 to be evaluated for treatment and receive counseling regarding HCV prevention. In addition to
8
9 physician education, patient education campaigns must also be developed to increase patient
10
11 compliance with testing recommendations made by their physicians.
12
13

14
15
16
17
18 In conclusion, we believe the screening tool described here will provide a simple and cost-effective
19
20 method of identifying and alerting PWID who are in need of additional, non-routine HCV screening
21
22 with notable predictive validity. A self-assessment method that helps individual PWID understand
23
24 their relative increased risk of infection provides the basis for increased uptake of screening,
25
26 diagnosis, and antiviral treatment among this population.
27
28

29
30
31 In summary, the tool described here has the potential to engage current PWID in timely and accurate
32
33 risk analysis, potentially modifying risk behaviour, and increasing uptake of HCV screening and
34
35 antiviral treatment in this population.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Article Summary****Article focus:**

- Although the risk factors for incident infection are well established, the literature suggests that a number of barriers may prevent PWID presenting for screening.
- Study developed a scoring tool based on demographic and injecting risk behaviors to identify those who require additional, non-routine serological screening for HCV by assessing their personal risk.

Key Messages:

- Current clinical practice guidelines recommend HCV screening of individuals with a history of injecting drugs.
- However, this recommendation focuses on a single risk factor (i.e. injecting drug use) whereas considering the cumulative effect of multiple risk factors among PWID can more precisely identify people in need of additional, non-routine screening.

Strengths and limitations:

- Our prediction equation is based on 11 years of data and more than 16,000 participants. Ideal risk assessment methods or prediction models should be derived from large representative samples.
- The study population is limited to those who participated in the ANSPS, which may result in selection bias.
- We were not able to differentiate between acute, recent and chronic infections.

1
2
3 **Competing interest:** None.
4

5 **Ethics approval:** Ethical approvals for the survey were obtained from Institutional Ethics Committees
6 associated with the investigators and participating NSP sites.
7
8

9
10
11 **Contributors:** HW and LM implemented the study, analysed the data and wrote the first draft. LM, JI,
12 LT and DW helped drafting, interpreting the data and finalizing the manuscript. All authors saw and
13 approved the final, submitted version of the manuscript.
14
15

16
17
18 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of
19 all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to
20 the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in
21 BMJ editions and any other BMJ PGL products and sublicences to exploit all subsidiary rights, as set
22 out in our licence (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>)."
23
24
25
26
27
28 should be made in the manuscript.
29

30 **Funding Source:** Australian Government Department of Health and Ageing.
31
32
33
34
35

36 **Provenance and peer review:** Not commissioned; externally peer reviewed.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- [1] McGinn T, O'Connor-Moore N, Alfandre D, Wisnivesky J. Validation of a Hepatitis C Screening Tool in Primary Care. *Arch Intern Med* **2008**; 168(18):2009-13.
- [2] Thorpe LE, Ouellet LJ, Hershov R et al. Risk of Hepatitis C Virus infection among Young Adult Injecting Drug Users Who Share Injecting Equipment. *American Journal of Epidemiology* **2002**; 155:7:645-653.
- [3] Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1976 through 1994. *New England Medical Journal* **1999**; 341:556-62.
- [4] Villano S A, Vlahov D, Nelson KE et al. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. *J Clin Microbiol* **1997**; 35: 3274-7;
- [5] Garfein RS, Doherty MC, Monterroso ER, et al. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. *J Acq Immune Defic Synd Hum Retrovirol* **1998**; 18:11-19.
- [6] Hahn JA, Page-Shafer K, Lum PJ et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. *J Infect Dis* **2002**; 186:1558-64.
- [7] Hagan H, Thiede H, Des Jarlais DC. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. *Epidemiology* **2004**; 15: 543-9.
- [8] Hagan H, Thiede H, Weiss NS et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. *Am J Public Health* **2001**; 91: 42-6.

- 1
2
3 [9] Falster K, Kaldor J and Maher L. Hepatitis C Virus acquisition among Injecting Drug Users: a cohort
4
5 analysis of a national repeated cross-sectional survey of needle and syringe program attendees in
6
7 Australia, 1995-2004. *Journal of Urban Health* **2008** [doi:10.1007/s11524-008-9330-7].
8
9
10
11 [10] Hahn JA, Page-Shafer K, Lum PJ et al. Hepatitis C virus seroconversion among young injection
12
13 drug users: relationships and risks. *J Infect Dis* **2002**; 186: 1558–64.
14
15
16
17 [11] Maher L, Jalaludin B, Chant KG et al. Incidence and risk factors for hepatitis C seroconversion in
18
19 injecting drug users in Australia. *Addiction* **2006**; 101(10): 1499-1508.
20
21
22
23 [12] Maher L, Li J, Jalaludin B et al. High hepatitis C incidence in new injecting drug users: a policy
24
25 failure? *Aust N Z J Public Health* **2007**; 31(1): 30-35.
26
27
28
29 [13] Patrick DM, Tyndall MW, Cornelisse PG et al. Incidence of hepatitis C virus infection among drug
30
31 users during an outbreak of HIV infection. *Can Med Assoc J* **2001**; 165: 889–95.
32
33
34
35 [14] Miller CL, Johnston C, Spittal PM et al. Opportunities for prevention: hepatitis C prevalence and
36
37 incidence in a cohort of young injection drug users. *Hepatology* **2002**; 36: 737–42.
38
39
40
41 [15] Davis M, Rhodes T. Beyond prevention? *International Journal of Drug Policy* **2004**; 15:123-31.
42
43
44 [16] National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually
45
46 transmissible infections in Australia. Annual Surveillance Report 2009. National Centre in HIV
47
48 Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW.
49
50
51
52 [17] NCHECR. Hepatitis C Virus Projections Working Group, Sydney: NCHECR, **2006**.
53
54
55 [18] Gerlach J, Diepolder H, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and
56
57 treatment-induced viral clearance. *Gastroenterology* **2003**; 125:80-8;
58
59
60

1
2
3 [19] Kamal SM, Fouly AE, Kamel RR et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of
4
5 onset of therapy on sustained virologic response. *Gastroenterology* **2006**; 130:632-638;
6
7

8
9 [20] Gregory JD, Hellard M, Matthews GV, et al. Effective Treatment of Injecting Drug Users with
10
11 recently acquired hepatitis C virus infection. *Gastroenterology* **2010**; 138:123-135;
12
13

14
15 [21] Topp L, Iversen, J, Wand H et al. Representativeness of injecting drug users who participate in HIV
16
17 surveillance: results from Australia's Needle and Syringe Program Survey. *J Acquir Immune Defic*
18
19 *Syndr* **2008**; 47(5), 632-638.
20
21

22
23 [22] MacDonald M, Crofts N, Kaldor J Transmission of hepatitis C virus: rates, routes, and cofactors.
24
25 *Epidemiol Rev* **1996**; 18(2), 137-148.
26
27

28
29 [23] MacDonald M, Wodak AD, Ali R et al. HIV prevalence and risk behavior in needle exchange
30
31 attenders: a national study. The Collaboration of Australian Needle Exchanges. *Med J Aust* **1997**;
32
33 166(5),237-240.
34
35

36
37 [24] MacDonald MA, Wodak AD, Dolan KA et al. Hepatitis C virus antibody prevalence among injecting
38
39 drug users at selected needle and syringe programs in Australia, 1995-1997. Collaboration of
40
41 Australian NSPs. *Med J Aust* **2000**; 172(2),57-61.
42
43

44
45 [25] Schmidt MI, Duncan BB, Bang H et al. Identifying individuals at high risk for diabetes: the
46
47 Atherosclerosis Risk in Communities study. *Diabetes Care* **2005**; 28:2013-2018.
48
49

50
51 [26] Gonen M. Analyzing Receiver Operating Characteristic Curves with SAS **2007**. Cary, NC: SAS
52
53 Institute;
54
55

56
57
58
59
60

1
2
3 [27] Sackett D, Straus SE, Richardson WS et al. Evidence- Based Medicine: How to Practice and Teach
4
5 EBM. 2nd ed. Philadelphia: Churchill Livingstone; **2000**.

6
7 [28] Wand H, Spiegelman D, Law M et al. Estimating population attributable risk for hepatitis C
8
9 seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Addiction **2009**, 104(12), 2049-2056(8).

[29] Maher L, Iversen J, Kaldor J. Measuring effectiveness of needle and syringe exchange programs
for prevention of HIV among injecting drug users: Response to Amundsen. Addiction **2006**;
101(12):1834-6.

[30] Volk M, Tocco R, Saini S, Lok A. Public health impact of antiviral therapy for hepatitis C in the
United States. Hepatology **2009**;50:1-6

[31] Edlin BR, Kresina TF, Raymond DB et al. Overcoming Barriers to Prevention, Care, and Treatment
of Hepatitis C in Illicit Drug Users. CID **2005**; 40 (Suppl 5): S276-S285.

[32] White B, Day C, Maher L. Self reported risk behavior among injecting drug users: Self versus
assisted questionnaire completion. AIDS Care **2007**; 19(3): 441-447.

[33] Vickers AJ, Basch E, Kattan MW. Against diagnosis. Ann Intern Med. **2008**; 149:200-3. [PMID:
18678847]

Table 1: Risk factors for Hepatitis C Virus (HCV)

Characteristics	HCV Seronegative N= 5,214 (49%)	HCV Seropositive N= 5,448 (51%)
Mean age at survey (\pm SD)	29 \pm 8	34 \pm 9
<25 years, %	35	16
25-29 years, %	24	19
30-39 years, %	29	37
40+ years, %	12	28
Female, %	33	35
Indigenous, %	8	10
Mean age at first injection (\pm SD)	20 \pm 6	19 \pm 6
Mean years of injecting (\pm SD)	9 \pm 7	15 \pm 9
<5 years, %	26	12
5-9 years, %	28	21
10-16 years, %	23	28
17+ years, %	14	40
Ever been in Prison, %	17	33
Been in prison last year, %	11	22
Drug injecting behaviors (last month)		
Drug injected, %		
Amphetamine/methamphetamine	51	28
Heroin	35	48
Cocaine	3	5
Methadone	4	8
Morphine	7	9
Buprenorphine	1	2
Others ¹	9	8
Injecting daily or more, %	50	58
Receptive sharing needle/syringe, %	15	18
Receptive sharing ancillary equipments ² , %	33	38
Injected by another, %	14	12
New needle syringe in every injection	72	68
Injected in Public	46	52

¹benzos, anabolic steroids, mixed drugs, other drugs or not reported

²water, spoon, filter, tourniquet

Table 2: Multivariable logistic regression: Odds Ratios (OR) and 95% confidence intervals (CI) for HCV infection scoring by age groups

	<25 N=2,686			25-29 N=2,291			30-39 N=3,563			40+ N=2,122		
	OR (P)	β^*10	Score	OR (P)	β^*10	Score	OR (P)	β^*10	Score	OR (P)	β^*10	Score
Sex												
Male	1	-	0	1			1			-		
Female	1.4	3.4	3	1.5 (<0.001)	4.1	4	1.4 (0.002)	3.3	3			
Indigenous												
No	-	-	-	-			1	-	-			
Yes							1.3 (0.04)	2.8	3			
Ever been in Prison?												
No	1	1	0	1			1			1		
Yes	2.2 (<0.001)	7.8	8	2.8 (<0.001)	10.2	10	1.9 (<0.001)	6.4	6	1.4 (0.003)	3.4	3
Years of injecting												
<5 year	1	-	0	1						1		
5-9 years	2.0 (<0.001)	6.8	7	1.7 (<0.001)	5.5	6	1.9 (<0.001)	6.5	7	1.5 (0.149)	3.7	4
10+ years	3.1 (<0.001)	11.1	11	2.4 (<0.001)	8.9	9	3.6 (<0.001)	12.7	13	4.6 (<0.001)	15.3	15
Drug last injected												
Amphetamine/methamphetamine	1	-	0	1			1	-		1		
Morphine	2.3 (<0.001)	8.3	8	1.7 (0.009)	5.5	6	1.9 (<0.001)	6.7	7	1.9 (<0.001)	6.7	7
Others ²	2.0 (<0.001)	6.7	7	1.6 (0.010)	4.7	5	1.8 (<0.001)	5.9	6	1.5 (0.053)	4.0	4
Heroin	3.0 (<0.001)	11.1	11	2.7 (<0.001)	10.0	10	3.0 (<0.001)	10.7	11	2.5 (<0.001)	9.0	9
Cocaine	6.4 (<0.001)	18.6	19	3.6 (<0.001)	12.7	13	3.0 (<0.001)	10.9	11	3.6 (<0.001)	12.8	13
Methadone	3.3 (<0.001)	11.3	11	3.4 (<0.001)	12.2	12	3.0 (<0.001)	11.0	11	3.1 (<0.001)	11.3	11
Buprenorphine	3.2 (0.003)	11.4	11	2.8 (0.004)	10.4	10	2.8 (0.001)	10.2	10	1.9 (0.141)	6.2	6
(Drug injecting behaviors last month)												
Injecting frequency												
Less than daily	1	-	0	1								
Daily or more	1.4 (0.001)	3.1	3	1.5 (<0.001)	4.0	4	-	-	-	-	-	
Receptive sharing needle/syringe												
No	-			1			1	-		-		
Yes	-			1.4 (0.005)	3.4	3	1.4 (0.002)	3.3	3			
Receptive sharing ancillary equipment²												
No	1	1	0	1						1		
Yes	1.3 (0.006)	2.5	3	1.3 (0.003)	3.0	3	-	-	-	1.5 (0.001)	3.8	4

¹benzos, anabolic steroids, mixed drugs, other drugs or not reported

²water, spoon, filter, tourniquet

Table 3: Odds Ratios (OR) and 95% confidence intervals (CI) & for HCV infection by quintiles of HCV scoring

	Age <25 years		Age 25-29 years		Age 30-39 years		Age 40 plus	
Development Data Set	OR (95% CI)	P ⁰	OR (95% CI)	P ⁰	OR (95% CI)	P ⁰	OR (95% CI)	P ⁰
HCV Risk score¹		<0.001		<0.001		<0.001		<0.001
Fifth 1	1		1		1		1	
Fifth 2	1.90 (1.33,2.69)		2.60 (1.88,3.57)		2.23 (1.72,2.89)		2.63 (1.94,3.58)	
Fifth 3	2.77 (1.92,4.01)		4.12 (3.00, 5.65)		4.07 (3.13,5.28)		4.56 (3.10,6.70)	
Fifth 4	5.40 (3.95,7.38)		4.85 (3.53,6.66)		5.40 (4.16,7.02)		5.86 (4.25,8.08)	
Fifth 5	10.31 (7.44,14.29)		12.40 (9.08,16.91)		9.10 (7.04,11.75)		7.78 (5.61,10.80)	
Population attributable risk for HCV score (%)² (95% CI)								
lowest v upper four fifth	78% (75%, 81%)		82% (80%, 84%)		80% (78%, 82%)		80% (77%, 82%)	
lower two v upper three fifth	74% (72%, 77%)		76% (74%, 78%)		74% (73%, 77%)		72% (69%, 74%)	
Validation Data Set								
HCV Risk score¹		<0.001		<0.001		<0.001		<0.001
Fifth 1	1		1		1		1	
Fifth 2	1.92 (1.12,3.28)		2.75 (1.73,4.38)		2.73 (1.94,3.85)		1.98 (1.30,3.02)	
Fifth 3	4.70 (2.75,8.04)		4.33 (2.78,6.77)		5.34 (3.74,7.63)		5.03 (2.78,9.10)	
Fifth 4	6.00 (3.76,9.56)		6.13 (3.93,9.56)		7.46 (5.19,10.74)		3.79 (2.44,5.87)	
Fifth 5	11.97 (7.41,19.32)		9.28 (6.07,14.19)		10.68 (7.56,15.10)		5.42 (3.50,8.42)	
Population attributable risk for HCV score (%)² (95% CI)								
lowest v upper four fifth	82% (79%, 85%)		80% (77%, 83%)		84% (82%, 85%)		73% (68%, 77%)	
lower two v upper three fifth	79% (76%, 81%)		74% (71%, 77%)		78% (76%, 79%)		67% (62%, 71%)	

⁰ Test for trend

¹ HCV score for age <25 was <7 for fifth 1, 7-<14 for fifth 2, 14-<17 for fifth 3, 17-<24 for fifth 4 and 24+ for fifth 5; for age 25-29 was <12 for fifth 1, 12-<17 for fifth 2, 17-<22 for fifth 3, 22-<26 for fifth 4 and 24+ for fifth 5; for age 30-39 was <13 for fifth 1, 13-<19 for fifth 2, 19-<24 for fifth 3, 24-<27 for fifth 4 and 27+ for fifth 5; for age 40 plus was <15 for fifth 1, 15-<22 for fifth 2, 22-<24 for fifth 3, 24-<27 for fifth 4 and 27+ for fifth 5;

Table 4: Optimal characteristics of HCV Scoring¹

	Age <25 years		Age 25-29 years		Age 30-39 years		Age 40 plus	
Score cut points ²	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity
Development Data Set (n=10,662)								
≥ 10	96%	17%	99%	9%	99%	7%	98%	10%
≥ 15	92%	32%	95%	23%	97%	15%	97%	19%
≥ 20	74%	60%	86%	42%	90%	36%	94%	24%
≥ 25	55%	74%	68%	64%	73%	57%	75%	54%
Validation Data Set-cross sectional (n= 5,465)								
≥ 10	96%	18%	99%	8%	99%	10%	99%	10%
≥ 15	94%	32%	95%	25%	97%	19%	97%	15%
≥ 20	76%	57%	88%	40%	87%	43%	94%	21%
≥ 25	59%	72%	67%	61%	73%	61%	74%	52%

¹HCV Score :

For age < 25: (female)*3+ (indigenous) *0 + (Injecting 5-9 years)*7 + (Injecting 10+ years) *11+ Morphine*8 + (other drugs e.g. benzos, anabolic steroids, mixed drugs, other drugs)*7 + (heroin)*11 + (cocaine)*19 + (methadone)*11 + (morphine)*8 + (Buprenorphine) *11 + (daily or more)*3 + (shared needle and syringe)*0 + (shared other equipment)*3 + (been in prison)*8

For age 25 -29 year: (female)*4+ (indigenous) *0 + (Injecting 5-9 years)*6 + (Injecting 10+ years) *9+ Morphine*6 + (other drugs e.g. benzos, anabolic steroids, mixed drugs, other drugs)*5 + (heroin)*10 + (cocaine)*13 + (methadone)*12 + (morphine)*5 + (Buprenorphine) *10 + (daily or more)*4 + (shared needle and syringe)*4 + (shared other equipment)*0 + (been in prison)*6

For age 30 -39 year: (female)*3+ (indigenous) *3 + (Injecting 5-9 years)*7 + (Injecting 10+ years) *13+ Morphine*7 + (other drugs e.g. benzos, anabolic steroids, mixed drugs, other drugs)*6 + (heroin)*11 + (cocaine)*11 + (methadone)*11 + (morphine)*7+ (Buprenorphine) *10 + (daily or more)*0 + (shared needle and syringe)*3 + (shared other equipment)*0 + (been in prison)*6

For age 40 + year: (female)*0+ (indigenous) *0 + (Injecting 5-9 years)*4 + (Injecting 10+ years) *15 + Morphine*7 + (other drugs e.g. benzos, anabolic steroids, mixed drugs, other drugs)*4 + (heroin)*9 + (cocaine)*13 + (methadone)*11 + (morphine)*7+ (Buprenorphine) *6 + (daily or more)*0 + (shared needle and syringe)*3 + (shared other equipment)*0 + (been in prison)*6

²Approximate cut points for the first, second, third and the fourth quintiles.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 5: Optimal characteristics of HCV Scoring using external prospective validation (N = 215)

Risk factors, No.	Validation with Prospective dataset	
	Hazard Ratio (95% CI)	P
Less than 2	Reference	
3	1.10 (0.74,1.60)	0.667
4	1.15 (0.78,1.65)	0.504
5	2.17 (1.45,3.17)	<0.001
6 or more	3.19 (2.30,5.51)	<0.001
Score cutpoints	Sensitivity	Specificity
≥ 10	89%	16%
≥ 15	78%	33%
≥ 20	60%	54%
≥ 25	41%	70%


For peer review only

Figure 1: Total score versus risk of HCV infection in cross-validation data set



36/bmjopen-2011-000387 on 4 January 2012. Downloaded from <http://bmjopen.bmj.com/> on August 17, 2023 by guest. Protected by copyright.

Figure 2: Sensitivity/Specificity for the prospective validation dataset:



36/bmjopen-2011-000387 on 4 January 2012. Downloaded from <http://bmjopen.bmj.com/> on August 17, 2023 by guest. Protected by copyright.

Correction

Wand H, Iversen J, Wilson D et al. Developing and validating a scoring tool for identifying people who inject drugs at increased risk of hepatitis C virus infection. *BMJ Open* 2012;**2**:e000387.

The following references were omitted from the paper:

20. Kshirsagar AV, Bang H, Bombardieri AS *et al.* A simple algorithm to predict incident kidney disease. *Arch Intern Med* 2008;**168**:2466–73.
25. Iversen J, Wand H, Gonnermann A, *et al.* Gender differences in hepatitis C antibody prevalence and risk behaviours amongst people who inject drugs in Australia 1998–2008. *Int J Drug Policy* 2010;**21**:471–76.
26. Bang H, Edwards AM, Bombardieri AS, *et al.* Development and validation of a patient self-assessment score for diabetes risk. *Ann Intern Med* 2009;**151**:775–83.
27. Bang H, Vupputuri S, Shoham DA, *et al.* Screening for Occult RENal Disease (SCORED): a simple prediction model for chronic kidney disease. *Arch Intern Med* 2007;**167**:374–81.
36. Trooskin SB, Navarro VJ, Winn RJ, *et al.* Hepatitis C risk assessment, testing and referral for treatment in urban primary care: Role of race and ethnicity. *World J Gastroenterol* 2007;**13**:1074–1078.

References in the manuscript should be re-numbered accordingly.

‘INTRODUCTION’, fourth paragraph should have read:

‘...in the development of the new prediction algorithm’: (1) the use of routinely available and minimally intrusive variables and (2) estimation of the cumulative effect of concurrent risk factors on the likelihood of²⁰ HCV prevalence. “We are unaware of any studies”²⁰ to date “that have quantified the cumulative effect of concurrent risk factors on the”²⁰ acquisition of...’

‘STUDY POPULATION’, second paragraph, should have read:

“A modified, third generation enzyme immunoassay (Abbott hepatitis C 3.0, Chicago, IL, USA) was used to test for HCV antibody. A modified cutoff value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cutoff ratio was greater than or equal to one on initial and subsequent testing”.²⁵

‘STATISTICAL ANALYSES’, third paragraph, should have read:

“We used descriptive statistics to characterize the groups according to antibody HCV serostatus: mean and standard deviation (SD) “for continuous variables and percentages for categorical variables”.²⁶ Logistic regression was used to create a predictive model based on the development data set. We used all non-missing observations available in the relevant analyses as only a small proportion of observations had any missing data (except for the variable “imprisonment history”).²⁶

‘Derivation of a Screening Score’, first paragraph, should have read:

“Using the development data set (n = 10 662), “we included a comprehensive list of predictors known to be associated” with HCV antibody seropositivity “in an initial model”.²⁶ “Specifically, we included the main effects of all variables listed in Table 1”.²⁶

““We first analyzed the univariate associations between the independent variables and”²⁷ HCV seropositivity. Backward elimination was used to reach the final multivariate “model, in which factors with the largest P value””.^{20,27}

“We then “created a weighted scoring system by rounding all regression coefficients”²⁶ up to the nearest integer (ie, “the smallest integer greater than”²⁷ the estimate). “This method was based on the β -coefficients (or log of the odds ratios) rather than odds ratios, which can be excessively influenced by only a few factors”.²⁷ Once the final model was defined, we created integer weights for each variable. We calculated these weights “by multiplying the model coefficients by 10. Using the rounded weights in the risk function, we estimated the participant-specific”²⁷ probabilities of HCV seropositivity and characterized the “degrees of risk based on cut-off points of the probability distribution””.^{20,27}

'Cross-sectional internal validation', second paragraph, should have read:

'We used the cross-sectional dataset to check the sensitivity and robustness of the new screening score. We computed standard validation measures: the proportion of antibody HCV seropositive specimens, sensitivity, specificity, positive likelihood and negative likelihood ratio and the area "under the receiver operating characteristic curve (AUC) as discrimination statistics. We also assessed the diagnostic characteristics of different cut-points based on the total score in the development as well as validation'.²⁶

'Prospective external validation', first paragraph, should have read:

'Using the Cox regression coefficients in the risk function, the participant-specific probability of HIV seroconversion was estimated. A rule to characterize different degrees of risk based on cut-off points of the probability distribution was then established. We also assessed the diagnostic features and characterized "different degrees of risk based on cut-off points of the probability distribution".²⁰

'RESULTS', second paragraph, should have read:

'Table 2 presents the final multivariate logistic regression model derived from the development data set by age groups'.²⁶

'...multiple categories "to capture the risk gradient, whereas other risk factors were binary".²⁶

'DISCUSSION', second paragraph, should have read:

'...of current HCV diagnoses and not incident HCV in the future, strong consistency in risk factors for the prediction incident events of HCV was shown in prospective validation of the tool.²⁶ Therefore, "we expect that the same set of risk factors in our model plays an important role in the prediction of future"²⁶....'

'DISCUSSION', fifth paragraph, should have read:

'Risk calculation approaches have been extensively "used in decision making about public health and clinical care and have even been proposed as an alternative to diagnosis for some diseases".^{26,33} Our risk calculation was based on a statistical method that yielded a systematic scoring system for carefully selected predictors, guided not only by numerical and scientific evidence but also feasibility perspectives.²⁶ We "chose categorized variables"²⁶ which highlighted the "important risk factors to motivate high-risk persons to be screened or to modify behaviors. This combination of factors may explain the enhanced properties of our"²⁶ scoring tool'.

'DISCUSSION', sixth paragraph, should have read:

"Ideal risk assessment methods or prediction models should be derived from large representative samples".²⁶

'DISCUSSION', seventh paragraph, should have read:

"Risk factor screening and identification allows for patients to be educated regarding the risks of injection drug use and needle sharing. Appropriate testing and diagnosis of HCV allows for the patient to be evaluated for treatment and receive counseling regarding"³⁶ HCV prevention. "In addition to physician education, patient education campaigns must also be developed to increase patient compliance with testing recommendations made by their physicians".³⁶

BMJ Open 2012;**2**:e000387corr1. doi:10.1136/bmjopen-2011-000387corr1